Immunodeficiency 92

Mendelian MONDO:0030498 Pathograph 12 Show in embeddings browser hereditary disease Inborn Error of Immunity Combined Immunodeficiency

Immunodeficiency 92 (IMD92) is an autosomal recessive combined immunodeficiency caused by biallelic loss-of-function variants in REL, which encodes c-Rel, one of the five NF-kB transcription factor subunits. c-Rel binds the promoters of a specific and immunologically coherent set of cytokine genes - IL-2, IFN-gamma, IL-12, IL-21 and IL-23 - so losing it removes transcriptional drive from the IL-12/IFN-gamma axis that controls intracellular-pathogen defence and from the IL-21 signalling that drives B-cell maturation, while leaving the other NF-kB subunits intact. The clinical result matches that transcriptional profile closely. The index patient had susceptibility to Mycobacterium tuberculosis, Salmonella, Cryptosporidium and cytomegalovirus - four intracellular or opportunistic organisms whose control depends on the IL-12/IFN-gamma axis - together with a B-cell arm of reduced IgG, undetectable IgA, a naive-shifted B-cell compartment with almost no switched memory B cells, and non-protective titres to tetanus and diphtheria despite boosters. The second patient adds chronic mucocutaneous candidiasis, chronic CMV viraemia, recurrent HSV-1, shingles, chronic gastrointestinal adenovirus and enterovirus replication, and cholangitis due to Cryptosporidium parvum. The response to BCG vaccination is where the two patients diverge, and it is the most clinically consequential fact in the entry. The index patient received live BCG, poliovirus and measles vaccines without sequelae, and only years later developed femoral M. tuberculosis osteomyelitis. The second patient developed DISSEMINATED BCG disease from the vaccine itself, with bone, lung and lymph node involvement. So the cellular defect is graded rather than absolute - but the grading has observed variance between patients, and live BCG has caused disseminated disease in one of the two vaccinated patients reported. Nothing here supports treating live vaccines as safe in this disease. The disease also has a myeloid arm that the immunodeficiency label does not advertise. Deep immunophenotyping of the second patient showed abolished IL-12 and IL-23 production by conventional type 1 dendritic cells and monocytes but NOT by cDC2s, and loss of CD86 induction on conventional dendritic cells - so c-Rel is required for antigen-presenting function as well as for lymphocyte cytokine output. The cDC1-versus-cDC2 selectivity is the sharpest single result in the disease and is not explained. IMD92 is exceptionally rare. Only three patients have been reported in total, the third in 2026, and the entry is written to keep that visible rather than to read like a characterised syndrome. The evidence is also very unevenly distributed: one patient received an extensive mechanistic workup, while the other two are described clinically. Where a claim rests on a single case, the entry says so in the evidence explanation rather than leaving the reader to infer it from a citation count - and one feature set reported in the third patient (craniosynostosis, language delay, epilepsy) is explicitly novel and unreplicated.

Ask OpenScientist

Ask a research question about Immunodeficiency 92. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
13
Phenotypes
4
Gaps
12
Pathograph
1
Genes
3
Medical Actions
1
Models
5
References
1
Deep Research
👪

Inheritance

1
Autosomal Recessive HP:0000007
Biallelic REL variants. Both fully described patients were homozygous and born to consanguineous parents; in the index family the variant was confirmed heterozygous in both parents and in a healthy brother, which is the segregation evidence for recessive inheritance.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:31103457 SUPPORT Human Clinical
"Sanger sequencing confirmed that the mutation is homozygous in the proband and heterozygous in his parents and healthy brother"
The segregation result establishing recessive inheritance. Note this is a single family, so it demonstrates recessive segregation in that pedigree rather than across a series.
?

Discussions and Knowledge Gaps

4
How much of this entry would survive a fourth and fifth patient?
KNOWLEDGE GAP imd92_evidence_base_is_three_cases
Three patients have been reported in total, and only two in enough detail to curate. Every phenotype except chronic diarrhoea rests on a single individual. The mechanism is nonetheless unusually credible for such a small series, for two reasons beyond coherence with c-Rel's promoter targets. Several features DO replicate across unrelated families - cryptosporidial cholangitis, the proliferation defect, CMV susceptibility. And the second patient's cure by HSCT is a rescue result: correcting both the immunological and the infectious phenotypes by replacing only the haematopoietic compartment establishes the disease as leukocyte-intrinsic. Readers should treat the pathophysiology chain as well-motivated and the phenotype frequencies as essentially unknown. This gap is attached to the disease as a whole because it conditions every claim in the entry rather than any one of them.
Are craniosynostosis, language delay and epilepsy part of IMD92, or coincidental findings in one consanguineous child?
OPEN QUESTION imd92_novel_features_third_patient
The third patient's report describes these as newly reported features. Two things argue for caution. There is no known role for c-Rel in cranial suture fusion or in neuronal excitability that would predict them, and the patient is from a consanguineous family, which is exactly the setting in which a second unrelated recessive disorder is likeliest. Recording them as PARTIAL evidence with an explicit note is the honest handling: they should be checked against the next reported patient rather than either dismissed or absorbed into the phenotype.
Why is IL-12/IL-23 production abolished in cDC1s and monocytes but preserved in cDC2s?
OPEN QUESTION imd92_cdc1_versus_cdc2_selectivity
This is the sharpest result in the disease and the least explained. Both dendritic-cell subsets express c-Rel and both make IL-12 family cytokines, so a simple "c-Rel binds the IL12B promoter" account predicts both should fail. Candidate explanations - a subset-specific difference in NF-kB subunit redundancy, differing dependence on c-Rel versus RelA at the same promoters, or a difference in the upstream signals each subset uses - have not been distinguished. It matters beyond this disease: cDC1 and cDC2 are being targeted separately in vaccine and cancer immunotherapy design, and a natural human knockout that separates them is unusually informative.
Why did BCG vaccination cause disseminated disease in one c-Rel-deficient patient and no sequelae in another?
OPEN QUESTION imd92_bcg_dissociation
Both fully described patients were BCG-vaccinated. The index patient had no clinical sequelae and developed femoral M. tuberculosis osteomyelitis only years later; the second patient developed disseminated BCG disease from the vaccine, with bone, lung and lymph node involvement. That dissociation is the strongest available evidence that the cellular defect is graded rather than absolute - the grading now has observed variance across patients instead of being inferred from a single tolerant case. What explains the variance is unknown. The alleles differ (an in-frame 18-residue deletion versus a frameshift at codon 134), so residual protein function is one candidate; redundancy among NF-kB subunits differing by individual, host genetic modifiers, and BCG strain or dose are others. Two patients cannot separate them. The practical stake is immediate and this entry does not hedge it: live BCG has caused disseminated disease in one of the two vaccinated c-Rel-deficient patients reported, so nothing here supports treating live vaccines as safe in this disease.

Pathophysiology

7
Biallelic Loss-of-Function REL Variants
The primary lesion is biallelic damage to REL, encoding c-Rel. Three homozygous alleles are published, all reaching the same endpoint - absent or severely reduced protein - by different molecular routes, and two of them are an instructive contrast at the same exon. The index patient carried a canonical DONOR splice-site variant AFTER exon 5 (c.535+1G>A), which forces use of cryptic donor and acceptor sites and produces an IN-FRAME transcript lacking 54 nucleotides - 18 residues - within the Rel homology domain, the DNA-binding and dimerisation module. The second patient carried the mirror lesion: c.395-1G>A, in the essential ACCEPTOR splice site of exon 5, common to both known REL isoforms. Skipping exon 5 there generates a FRAMESHIFT and a premature stop at codon 134. Same exon, opposite splice boundary, and a different class of consequence. The third patient carried a homozygous frameshift, c.24del p.(Tyr9Ilefs*2), introducing a premature stop almost at the start of the coding sequence.
REL hgnc:9954 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves REL (hgnc:9954). hgnc:9954 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (4 references)
PMID:31103457 SUPPORT Human Clinical
"The mutant transcript lacks 54 nucleotides encoding 18 residues within the Rel homology domain"
Characterises the index allele's molecular consequence at transcript level, and locates it in the functionally critical domain.
PMID:42117340 SUPPORT Human Clinical
"identified a novel homozygous frameshift variant (NM_001291746.4) REL:c.24del p.(Tyr9Ilefs*2). This variant introduces a very early premature stop codon."
A further allele class, from the third reported patient, independently confirming that REL loss of function causes the disease.
PMID:34623332 SUPPORT Human Clinical
"located in the essential acceptor splice site of exon 5 common to the 2 known REL isoforms"
The second patient's allele, c.395-1G>A. It is the mirror of the index allele - acceptor rather than donor side of the same exon - and it affects both known REL isoforms.
+ 1 more reference
Absent c-Rel Protein
Both patients were shown by immunoblot of peripheral blood mononuclear cells to lack c-Rel protein - absent with no detectable truncation product in the index patient, severely reduced in the third. The third report adds an important specificity control: p65 (RelA) levels were preserved, so the lesion is subunit-selective rather than a general collapse of NF-kB. This is what makes the disease informative about c-Rel's non-redundant role in humans.
REL hgnc:9954 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves REL (hgnc:9954). hgnc:9954 is a gene from the HUGO Gene Nomenclature Committee.
canonical NF-kappaB signal transduction GO:0007249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves canonical NF-kappaB signal transduction (GO:0007249), qualified as loss of function. GO:0007249 is a biological process from the Gene Ontology. ⇓ LOSS OF FUNCTION
Show evidence (2 references)
PMID:31103457 SUPPORT Human Clinical
"immunoblotting using an antibody specific to the protein's N-terminus demonstrated the absence of c-Rel protein in the patient's peripheral blood mononuclear cells (PBMCs) with no detectable truncation products, indicating that the mutation abrogates protein expression"
Direct protein-level demonstration that the splice allele abolishes c-Rel, closing the gap between genotype and functional deficiency.
PMID:42117340 SUPPORT Human Clinical
"Western blot analysis of peripheral blood mononuclear cells demonstrated a severe reduction of c Rel protein expression with preserved p65 levels, confirming its functional impact."
Independent protein-level confirmation, and the preserved-p65 control establishing that the deficiency is subunit-selective.
Failed Transcription of c-Rel-Dependent Cytokine Genes
c-Rel binds the promoters of IL-2, IFN-gamma, IL-12, IL-21 and IL-23. That target set is not a random collection: IL-12 and IFN-gamma are the axis controlling macrophage activation against intracellular pathogens, IL-2 drives T-cell clonal expansion, and IL-21 is the principal T-follicular-helper signal for B-cell class switching and memory formation. The disease phenotype can be read almost directly off this promoter list, which is the strongest argument that the mechanism is correct despite the tiny patient number.
positive regulation of transcription by RNA polymerase II GO:0045944 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased positive regulation of transcription by RNA polymerase II (GO:0045944). GO:0045944 is a biological process from the Gene Ontology. ↓ DECREASED interleukin-12 production GO:0032615 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased interleukin-12 production (GO:0032615). GO:0032615 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (4 references)
PMID:31103457 SUPPORT Human Clinical
"c-Rel binds to the promoters of genes that encode cytokines important for immunity against infectious pathogens, including IL-2, IFN-γ, IL-12, IL-21, and IL-23."
States the promoter target set this node depends on. This is the report's background statement of established c-Rel biology rather than a measurement in the patient; the measurement is the next two items.
PMID:34623332 SUPPORT Human Clinical
"Functional deficits of myeloid cells included the abolition of IL-12 and IL-23 production by conventional DC1s (cDC1s) and monocytes, but not cDC2s."
Direct measurement of failed IL-12 and IL-23 output in patient cells - and the cell-type selectivity, which no promoter-binding argument predicts.
PMID:34623332 SUPPORT Human Clinical
"Functional deficits of lymphoid cells included reduced IL-2 production by naive T cells, correlating with low proliferation and survival rates and poor production of Th1, Th2, and Th17 cytokines by memory CD4+ T cells."
Direct measurement of the lymphoid cytokine deficit in patient cells, linking reduced IL-2 to the observed proliferation and survival failure.
+ 1 more reference
Myeloid Antigen-Presenting Cell Failure
The arm that the phrase "combined immunodeficiency" hides. c-Rel is required in conventional type 1 dendritic cells and monocytes for IL-12 and IL-23 production, and its loss abolishes that output - while cDC2s are spared. It is also required for CD86 induction on conventional dendritic cells, so the defect is not only cytokine secretion but antigen-presenting capacity itself. Since IL-12 from cDC1s is what licenses Th1 differentiation and IFN-gamma-dependent macrophage activation, this node explains the mycobacterial and intracellular susceptibility without needing to invoke a T-cell-intrinsic defect at all - though the entry models both, because both are measured.
conventional dendritic cell CL:0000990 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves conventional dendritic cell (CL:0000990). CL:0000990 is a cell type from the Cell Ontology. monocyte CL:0000576 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves monocyte (CL:0000576). CL:0000576 is a cell type from the Cell Ontology.
interleukin-23 production GO:0032627 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent interleukin-23 production (GO:0032627). GO:0032627 is a biological process from the Gene Ontology. ∅ ABSENT antigen processing and presentation GO:0019882 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased antigen processing and presentation (GO:0019882). GO:0019882 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (2 references)
PMID:34623332 SUPPORT Human Clinical
"Functional deficits of myeloid cells included the abolition of IL-12 and IL-23 production by conventional DC1s (cDC1s) and monocytes, but not cDC2s."
The measurement defining this node, including the cDC1/cDC2 dissociation that makes it a selective rather than global myeloid defect.
PMID:34623332 SUPPORT Human Clinical
"c-Rel was also required for induction of CD86 expression on, and thus antigen-presenting cell function of, cDCs."
Extends the defect from cytokine output to costimulation and antigen presentation.
Impaired T Cell Activation and Proliferation
The index patient had numerically increased CD4+ and CD8+ T cells but reduced memory CD4+CD45RO+ cells and reduced proliferation to phytohaemagglutinin. The dissociation is informative: T cells are made and survive, but do not respond - a functional rather than a numerical T-cell defect, which is why the disease presents as combined immunodeficiency without lymphopenia.
T cell CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology.
T cell proliferation GO:0042098 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased T cell proliferation (GO:0042098). GO:0042098 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (2 references)
PMID:31103457 SUPPORT Human Clinical
"He had increased numbers of CD4+ and CD8+ T cells with decreased memory CD4+CD45RO+ T cells, and reduced proliferation to phytohemagglutinin (PHA)"
The immunophenotyping and functional proliferation result underlying this node, from the index patient.
PMID:34623332 SUPPORT Human Clinical
"PBMCs from P did not proliferate, or only weakly proliferated, in vitro in response to any of the physiological"
Independent replication of the proliferation defect in the second patient, and against PHYSIOLOGICAL antigens rather than a mitogen - the full sentence lists tuberculin, candidin, tetanus toxoid and CMV antigens, which ties the T-cell node directly to three of the patient's four infections. The snippet stops before "stimuli" because the cached text hyphenates that word across a line break.
Impaired B Cell Maturation and Class Switching
B-cell lymphopenia with impaired proliferation to CD40 ligand plus IL-21, reduced IgG and undetectable IgA, and non-protective tetanus and diphtheria titres despite boosters. Immunophenotyping at 9 years showed the compartment stuck at the naive stage - 85% naive CD19+IgD+CD27- B cells against a normal range of 47.3-77%, and 0.3% switched memory CD19+CD27+IgD- cells against a reference range of 10.0-30.4%. The failure of proliferation specifically to CD40L+IL-21 connects the cellular defect back to the c-Rel-dependent cytokine IL-21.
B cell CL:0000236 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves B cell (CL:0000236). CL:0000236 is a cell type from the Cell Ontology. memory B cell CL:0000787 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves memory B cell (CL:0000787). CL:0000787 is a cell type from the Cell Ontology.
B cell proliferation GO:0042100 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased B cell proliferation (GO:0042100). GO:0042100 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (3 references)
PMID:31103457 SUPPORT Human Clinical
"He had B cell lymphopenia, impaired B cell proliferation upon stimulation with CD40 ligand + IL-21, reduced IgG and undetectable IgA levels, and non-protective titers to the tetanus and diphtheria vaccines despite booster vaccinations"
The humoral phenotype, including the IL-21-specific proliferation defect that links it to the transcriptional node upstream. Single patient.
PMID:31103457 SUPPORT Human Clinical
"revealed a predominance of naïve CD19+IgD+CD27− B cells (85%; normal 47.3 – 77%) and reduced percentages of switched memory CD19+CD27+IgD− B cells (0.3%; reference range 10.0 – 30.4)"
Quantifies the maturation block against reference ranges, showing the compartment arrested before class switching.
PMID:34623332 SUPPORT Human Clinical
"The patient's naive B cells displayed impaired MYC and BCL2L1 induction, compromising B cell survival and proliferation and preventing their differentiation into Ig-secreting plasmablasts."
Identifies the B-cell-intrinsic transcriptional targets - MYC and BCL2L1 - whose failed induction blocks plasmablast differentiation, which is a different and more specific claim than the IL-21 route modelled upstream.
Susceptibility to Intracellular and Opportunistic Pathogens
The clinical endpoint. The index patient's organisms - Mycobacterium tuberculosis, Salmonella enterica, Cryptosporidium and cytomegalovirus - are precisely the set controlled by the IL-12/IFN-gamma axis and by cellular immunity, and the coherence of that list with c-Rel's promoter targets is the main evidence that the mechanism is right. The second patient's list is broader still - BCG disease, chronic mucocutaneous candidiasis, cryptosporidiosis, CMV disease and shingles - and adds a fungal axis that the IL-23/Th17 arm explains. Chronic cryptosporidiosis led on to cholangitis in BOTH fully described patients, the classic biliary complication of that organism in immunodeficiency, which makes it one of the better-replicated features here. The defect is graded rather than absolute, but the evidence for that is a DISSOCIATION rather than a uniform observation: the index patient tolerated live BCG, poliovirus and measles vaccines without sequelae, while the second patient developed disseminated BCG disease from the vaccine. Both are true, and the entry does not average them.
Show evidence (5 references)
PMID:31103457 SUPPORT Human Clinical
"This study reports a homozygous mutation in REL abrogating c-Rel protein expression in a patient with combined immunodeficiency characterized by susceptibility to Mycobacterium tuberculosis, Salmonella, Cryptosporidium, and cytomegalovirus."
The defining infectious susceptibility profile, stated as the report's headline finding.
PMID:31103457 SUPPORT Human Clinical
"He received live vaccinations against poliovirus, measles, and Bacille Calmette-Guerin (BCG) without clinical sequelae."
One half of the vaccine dissociation: the INDEX patient tolerated live vaccines, which is not the profile of severe combined immunodeficiency. Read with the next item, which reports the opposite outcome in the second patient.
PMID:34623332 SUPPORT Human Clinical
"disseminated BCG disease following vaccination (BCG-osis), with bone, lung, and lymph node involvement"
The other half, and the clinically decisive one: the second patient developed disseminated disease from the BCG vaccine itself. This is why the entry does not present live vaccines as tolerated in this disease.
+ 2 more references

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Immunodeficiency 92 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

13
Blood 2
Decreased Circulating IgG Decreased circulating IgG concentration HP:0004315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased circulating IgG concentration (HP:0004315). HP:0004315 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31103457 SUPPORT Human Clinical
"reduced IgG and undetectable IgA levels, and non-protective titers to the tetanus and diphtheria vaccines despite booster vaccinations"
The humoral deficiency and the functional vaccine-response failure. Single patient.
Decreased Circulating IgA Decreased circulating IgA concentration HP:0002720 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased circulating IgA concentration (HP:0002720). HP:0002720 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31103457 SUPPORT Human Clinical
"reduced IgG and undetectable IgA levels, and non-protective titers to the tetanus and diphtheria vaccines despite booster vaccinations"
Records the undetectable IgA. Single patient.
Digestive 2
Chronic Diarrhea HP:0002028 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic diarrhea (HP:0002028), qualified as temporality chronic. HP:0002028 is a phenotype from the Human Phenotype Ontology.
Temporal: CHRONIC
No frequency band is asserted, for the reason this entry states elsewhere: at n=3 a FrequencyEnum band is a statistical fiction. Two of three is in any case FREQUENT, not VERY_FREQUENT, and the description carries the information honestly without a band.
Show evidence (2 references)
PMID:42117340 SUPPORT Human Clinical
"a third case is described of a 5-year-old Moroccan child with combined immunodeficiency presenting with chronic diarrhea and recurrent opportunistic infections"
Chronic diarrhoea as the presenting feature in the third patient, replicating the index presentation.
PMID:31103457 SUPPORT Human Clinical
"At 30 months of age, he developed chronic diarrhea associated with multiple infections, including Salmonella enteritica, cytomegalovirus (CMV), and Cryptosporidium."
The index patient's presenting chronic diarrhoea and its causative organisms.
Sclerosing Cholangitis HP:0030991 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sclerosing cholangitis (HP:0030991). HP:0030991 is a phenotype from the Human Phenotype Ontology.
Replicated across both fully described patients, in unrelated families, with the same aetiology - cryptosporidial biliary infection. That makes it one of the better-supported features in the entry, despite being secondary to a treatable infection rather than intrinsic to the mechanism.
Show evidence (2 references)
PMID:31103457 SUPPORT Human Clinical
"In the setting of chronic cryptosporidiosis, he developed hepatomegaly and sclerosing cholangitis."
The index patient's cholangitis, explicitly attributed to the cryptosporidial infection rather than to c-Rel deficiency directly.
PMID:34623332 SUPPORT Human Clinical
"cholangitis due to C. parvum, esophageal candidiasis"
Independent replication in the second patient, with the same organism - which is what upgrades this from a single-patient complication to a reproducible consequence of the immunodeficiency.
Head and Neck 1
Craniosynostosis HP:0001363 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Craniosynostosis (HP:0001363). HP:0001363 is a phenotype from the Human Phenotype Ontology.
A single unreplicated observation in a consanguineous child, where a second recessive condition is a live alternative explanation. Recorded so it can be checked against future cases, not asserted as a disease feature. See the discussion `imd92_novel_features_third_patient`.
Show evidence (1 reference)
PMID:42117340 SUPPORT Human Clinical
"alongside newly reported features including craniosynostosis, language delay, and epilepsy"
Graded PARTIAL. The authors describe these as newly reported; one patient in a consanguineous family is not sufficient to attribute a non-immunological feature to REL.
Immune 1
Combined Immunodeficiency OBLIGATE HP:0005387 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Combined immunodeficiency (HP:0005387). HP:0005387 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42117340 SUPPORT Human Clinical
"immunodeficiency 92 (IMD92), an extremely rare autosomal recessive disorder due to c Rel deficiency that results from pathogenic variants of the REL gene"
Names the entity and its immunodeficiency character; combined immunodeficiency is the presentation in both fully described patients.
Nervous System 1
Epilepsy Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
As for craniosynostosis - single unreplicated report in a consanguineous child.
Show evidence (1 reference)
PMID:42117340 SUPPORT Human Clinical
"alongside newly reported features including craniosynostosis, language delay, and epilepsy"
Same single-patient limitation as craniosynostosis.
Other 6
Recurrent Mycobacterial Infection Recurrent mycobacterial infections HP:0011274 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent mycobacterial infections (HP:0011274). HP:0011274 is a phenotype from the Human Phenotype Ontology.
Reported in one patient. No frequency is asserted; with three cases in total, a FrequencyEnum band would be a statistical fiction.
Show evidence (1 reference)
PMID:31103457 SUPPORT Human Clinical
"Despite vaccination with BCG, he developed femoral Mycobacterium tuberculosis osteomyelitis at 7 years of age that was successfully treated with isoniazid, rifampin, pyrazinamide, and ethambutol."
Documents the mycobacterial disease and its successful treatment. Graded PARTIAL because a single patient's infection establishes susceptibility as possible, not as a characteristic disease feature.
Disseminated BCG Disease BCGosis HP:0020087 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is BCGosis (HP:0020087). HP:0020087 is a phenotype from the Human Phenotype Ontology.
One of two BCG-vaccinated patients. The index patient tolerated BCG without sequelae. Both outcomes are recorded, and no frequency is asserted - see the discussion `imd92_bcg_dissociation`.
Show evidence (2 references)
PMID:34623332 SUPPORT Human Clinical
"disseminated BCG disease following vaccination (BCG-osis), with bone, lung, and lymph node involvement"
The disseminated BCG disease and its three sites, attributed to the vaccination.
PMID:34623332 SUPPORT Human Clinical
"Disseminated BCG-osis with bone and lung lesions, cholangitis due to C. parvum, esophageal candidiasis"
The imaging/clinical summary of the second patient's three defining complications.
Chronic Mucocutaneous Candidiasis HP:0002728 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Chronic mucocutaneous candidiasis (HP:0002728), qualified as temporality chronic. HP:0002728 is a phenotype from the Human Phenotype Ontology.
Temporal: CHRONIC
Show evidence (2 references)
PMID:34623332 SUPPORT Human Clinical
"we studied a child with BCG disease, CMC, cryptosporidiosis, CMV disease, and shingles"
Records CMC among the second patient's defining infections.
PMID:34623332 SUPPORT Human Clinical
"poor production of Th1, Th2, and Th17 cytokines by memory CD4+ T cells"
The measured Th17 deficit that connects the candidiasis to the entry's transcriptional node - the IL-23/Th17 branch of c-Rel's promoter list.
Severe Cytomegalovirus Infection HP:0031692 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Severe cytomegalovirus infection (HP:0031692). HP:0031692 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34623332 SUPPORT Human Clinical
"we studied a child with BCG disease, CMC, cryptosporidiosis, CMV disease, and shingles"
CMV disease in the second patient, replicating the index patient's CMV susceptibility.
Recurrent Viral Infections HP:0004429 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Recurrent viral infections (HP:0004429), qualified as temporality recurrent. HP:0004429 is a phenotype from the Human Phenotype Ontology.
Temporal: RECURRENT
Show evidence (1 reference)
PMID:34623332 SUPPORT Human Clinical
"P had various infections from early childhood onwards: CMC, including recurrent esophagitis; chronic CMV viremia with recurrent fever; recurrent oral herpes simplex virus 1 (HSV-1) lesions"
The second patient's viral infection profile, listed with the chronicity and recurrence this phenotype records.
Reduced Memory Lymphocyte Subsets Decreased memory B cell proportion HP:0030374 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Decreased proportion of memory B cells, annotated with Decreased memory B cell proportion (HP:0030374). HP:0030374 is a phenotype from the Human Phenotype Ontology.
The HPO binding captures only the memory-B-cell component. There is no single HP term for the pattern actually observed - a coordinated reduction across NK, Temra CD8, memory CD4/Th1, Treg and memory B compartments with other subsets normal - so the binding necessarily understates the finding, and the description carries the rest.
Show evidence (1 reference)
PMID:34623332 SUPPORT Human Clinical
"The patient had low frequencies of NK, effector memory cells reexpressing CD45RA (Temra) CD8+ T cells, memory CD4+ T cells, including Th1 and Th1*, Tregs, and memory B cells, whereas the counts and proportions of other leukocyte subsets were normal."
The immunophenotyping result, including the explicit statement that other subsets were normal, which makes the deficit selective.
🧬

Genetic Associations

1
REL
Gene: REL hgnc:9954 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is REL (hgnc:9954). hgnc:9954 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:31103457 SUPPORT Human Clinical
"a homozygous mutation in the canonical donor splice-site after exon 5 of REL (NM_002908.3: c.535+1G>A) was considered the most likely pathogenic variant due to the known contribution of c-Rel in T and B cell activation and cytokine secretion"
Names the index allele and the reasoning by which it was selected from 80 rare candidate variants.
PMID:42117340 SUPPORT Human Clinical
"This report expands the mutational spectrum of REL and further supports the critical, non-redundant role of c-Rel in human immune homeostasis."
The second report's own statement of what it adds - an expanded allelic spectrum and support for non-redundancy.
💊

Medical Actions

3
Immunoglobulin Replacement
Action: immunoglobulin therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunoglobulin therapy (NCIT:C62710). NCIT:C62710 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunoglobulin Therapy NCIT:C62710
The supportive standard for a combined immunodeficiency with humoral failure. The index patient received intravenous immunoglobulin. This is the management actually reported; it is not disease-specific and no outcome data exist for it in IMD92.
Mechanism Target:
Impaired B Cell Maturation and Class Switching — Replacement immunoglobulin substitutes for the antibody the patient's own arrested B-cell compartment cannot make.
Show evidence (1 reference)
PMID:31103457 SUPPORT Human Clinical
"He is currently treated with intravenous immunoglobulin and prophylactic antibiotics while undergoing evaluation for hematopoietic stem cell transplantation."
Reports the treatment given. It documents practice in one patient, with no outcome measure, so it establishes what was done rather than that it works.
Antimicrobial Prophylaxis
Action: antibiotic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antibiotic therapy (NCIT:C15620). NCIT:C15620 is a clinical intervention from the NCI Thesaurus. Ontology label: Antibiotic Therapy NCIT:C15620
Prophylactic antibiotics alongside immunoglobulin replacement in the index patient. Split from the immunoglobulin entry so that the modality and the mechanism it targets are separately queryable - the two interventions address different arms of the defect.
Mechanism Target:
Susceptibility to Intracellular and Opportunistic Pathogens — Prophylaxis substitutes for the cellular immunity the patient cannot mount, rather than correcting it.
Show evidence (1 reference)
PMID:31103457 SUPPORT Human Clinical
"He is currently treated with intravenous immunoglobulin and prophylactic antibiotics while undergoing evaluation for hematopoietic stem cell transplantation."
The same sentence documents both arms of the supportive regimen; it reports practice in one patient with no outcome measure.
Hematopoietic Stem Cell Transplantation
Action: hematopoietic cell transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hematopoietic cell transplantation (NCIT:C15431). NCIT:C15431 is a clinical intervention from the NCI Thesaurus. Ontology label: Hematopoietic Cell Transplantation NCIT:C15431
The curative option, and it has been done. The second patient was transplanted in 2017 and her infectious phenotypes were cured. The index patient was under evaluation for transplantation at the time of his report. The cure is worth more to this entry than a treatment outcome. Because HSCT replaces only the haematopoietic compartment, simultaneous correction of the immunological and the infectious phenotypes is a rescue experiment: it establishes that the disease is caused by intrinsic defects of leukocytes rather than by anything c-Rel does elsewhere. That is direct support for the pathograph modelled above, not just for the treatment.
Mechanism Target:
Absent c-Rel Protein — Replacing the haematopoietic compartment with donor cells restores c-Rel expression in the lineages where it is required.
Show evidence (2 references)
PMID:31103457 SUPPORT Human Clinical
"while undergoing evaluation for hematopoietic stem cell transplantation"
Graded PARTIAL - it establishes that transplantation was considered clinically appropriate for the index patient, but reports an evaluation rather than an outcome. The next item reports the outcome.
PMID:34623332 SUPPORT Human Clinical
"The simultaneous correction of the immunological and infectious phenotypes by HSCT confirmed that the patient’s immunodeficiency was caused by severe intrinsic defects of leukocytes."
The cure, and the inference the authors draw from it. Because HSCT replaces only haematopoietic cells, correcting both phenotypes at once is rescue evidence that the disease is leukocyte-intrinsic - which supports the whole pathograph, not only this treatment.
📊

Prevalence

1
Worldwide, published cases
Cases In Literature Ultra Rare
Three patients reported in total as of the 2026 report, which described the third and stated that two had previously been confirmed. No population prevalence estimate is possible.
Show evidence (1 reference)
PMID:42117340 SUPPORT Human Clinical
"Up untill now, only two patients with confirmed pathogenic REL variants have been reported."
Gives the published case count immediately before this report added the third. Quoted verbatim including the source's typographical error, as required for snippet verification.
🐁

Animal Models

1
Rel-knockout mouse
The germline c-rel knockout mouse, described in 1995 - nearly a quarter of a century before the first human patient, and the reason c-Rel was an immediate candidate when that patient was sequenced.
Species
Mouse
Genotype
c-rel-/- (germline inactivation)
Publication
{ }

Source YAML

click to show
name: Immunodeficiency 92
creation_date: "2026-08-28T00:00:00Z"
category: Mendelian
disease_term:
  preferred_term: c-Rel deficiency (immunodeficiency 92)
  term:
    id: MONDO:0030498
    label: immunodeficiency 92
description: >-
  Immunodeficiency 92 (IMD92) is an autosomal recessive combined immunodeficiency
  caused by biallelic loss-of-function variants in REL, which encodes c-Rel, one of
  the five NF-kB transcription factor subunits. c-Rel binds the promoters of a
  specific and immunologically coherent set of cytokine genes - IL-2, IFN-gamma,
  IL-12, IL-21 and IL-23 - so losing it removes transcriptional drive from the
  IL-12/IFN-gamma axis that controls intracellular-pathogen defence and from the
  IL-21 signalling that drives B-cell maturation, while leaving the other NF-kB
  subunits intact.
  The clinical result matches that transcriptional profile closely. The index
  patient had susceptibility to Mycobacterium tuberculosis, Salmonella,
  Cryptosporidium and cytomegalovirus - four intracellular or opportunistic
  organisms whose control depends on the IL-12/IFN-gamma axis - together with a
  B-cell arm of reduced IgG, undetectable IgA, a naive-shifted B-cell compartment
  with almost no switched memory B cells, and non-protective titres to tetanus and
  diphtheria despite boosters. The second patient adds chronic mucocutaneous
  candidiasis, chronic CMV viraemia, recurrent HSV-1, shingles, chronic
  gastrointestinal adenovirus and enterovirus replication, and cholangitis due to
  Cryptosporidium parvum.
  The response to BCG vaccination is where the two patients diverge, and it is
  the most clinically consequential fact in the entry. The index patient received
  live BCG, poliovirus and measles vaccines without sequelae, and only years later
  developed femoral M. tuberculosis osteomyelitis. The second patient developed
  DISSEMINATED BCG disease from the vaccine itself, with bone, lung and lymph node
  involvement. So the cellular defect is graded rather than absolute - but the
  grading has observed variance between patients, and live BCG has caused
  disseminated disease in one of the two vaccinated patients reported. Nothing
  here supports treating live vaccines as safe in this disease.
  The disease also has a myeloid arm that the immunodeficiency label does not
  advertise. Deep immunophenotyping of the second patient showed abolished IL-12
  and IL-23 production by conventional type 1 dendritic cells and monocytes but
  NOT by cDC2s, and loss of CD86 induction on conventional dendritic cells - so
  c-Rel is required for antigen-presenting function as well as for lymphocyte
  cytokine output. The cDC1-versus-cDC2 selectivity is the sharpest single result
  in the disease and is not explained.
  IMD92 is exceptionally rare. Only three patients have been reported in total, the
  third in 2026, and the entry is written to keep that visible rather than to read
  like a characterised syndrome. The evidence is also very unevenly distributed:
  one patient received an extensive mechanistic workup, while the other two are
  described clinically. Where a claim rests on a single case, the entry says so in
  the evidence explanation rather than leaving the reader to infer it from a
  citation count - and one feature set reported in the third patient
  (craniosynostosis, language delay, epilepsy) is explicitly novel and
  unreplicated.
parents:
- hereditary disease
- Inborn Error of Immunity
- Combined Immunodeficiency
synonyms:
- IMD92
- c-Rel deficiency
- immunodeficiency due to REL deficiency
- REL deficiency
notes: >-
  Evidence base. The entire disease literature is three patients. This has a
  practical consequence for reading the entry: `evidence_source: HUMAN_CLINICAL`
  here means a single patient, not a cohort - and it means something quite
  different again for PMID:34623332, which is a single patient subjected to an
  extensive mechanistic workup, and is the strongest evidence in the entry despite
  n=1. The schema has no slot that distinguishes any of these, so the distinction
  is carried in prose in each `explanation`. See the discussion
  `imd92_evidence_base_is_three_cases`.

  Scope. The MONDO parent is the broad `immunodeficiency disease`. Once curated,
  IMD92 is a candidate member of the existing `kb/groupings/Inborn_Errors_of_Immunity.yaml`
  grouping; adding it there is a separate change and is not made in this entry.

  Not to be confused with NFKB1 or NFKB2 deficiency, which are commoner NF-kB
  pathway inborn errors of immunity presenting as common variable immunodeficiency,
  or with the many oncology papers on c-Rel - REL is an established proto-oncogene,
  and a literature search on the gene returns mostly cancer biology unrelated to
  this disease.
inheritance:
- name: Autosomal Recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Biallelic REL variants. Both fully described patients were homozygous and born
    to consanguineous parents; in the index family the variant was confirmed
    heterozygous in both parents and in a healthy brother, which is the segregation
    evidence for recessive inheritance.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sanger sequencing confirmed that the mutation is homozygous in the proband and heterozygous in his parents and healthy brother"
    explanation: >-
      The segregation result establishing recessive inheritance. Note this is a
      single family, so it demonstrates recessive segregation in that pedigree
      rather than across a series.
prevalence:
- population: Worldwide, published cases
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Three patients reported in total as of the 2026 report, which described the
    third and stated that two had previously been confirmed. No population
    prevalence estimate is possible.
  evidence:
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Up untill now, only two patients with confirmed pathogenic REL variants have been reported."
    explanation: >-
      Gives the published case count immediately before this report added the
      third. Quoted verbatim including the source's typographical error, as
      required for snippet verification.
pathophysiology:
- name: Biallelic Loss-of-Function REL Variants
  biological_scale: MOLECULAR
  description: >-
    The primary lesion is biallelic damage to REL, encoding c-Rel. Three
    homozygous alleles are published, all reaching the same endpoint - absent or
    severely reduced protein - by different molecular routes, and two of them are
    an instructive contrast at the same exon.
    The index patient carried a canonical DONOR splice-site variant AFTER exon 5
    (c.535+1G>A), which forces use of cryptic donor and acceptor sites and produces
    an IN-FRAME transcript lacking 54 nucleotides - 18 residues - within the Rel
    homology domain, the DNA-binding and dimerisation module.
    The second patient carried the mirror lesion: c.395-1G>A, in the essential
    ACCEPTOR splice site of exon 5, common to both known REL isoforms. Skipping
    exon 5 there generates a FRAMESHIFT and a premature stop at codon 134. Same
    exon, opposite splice boundary, and a different class of consequence.
    The third patient carried a homozygous frameshift, c.24del p.(Tyr9Ilefs*2),
    introducing a premature stop almost at the start of the coding sequence.
  genes:
  - preferred_term: REL
    term:
      id: hgnc:9954
      label: REL
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mutant transcript lacks 54 nucleotides encoding 18 residues within the Rel homology domain"
    explanation: Characterises the index allele's molecular consequence at transcript level, and locates it in the functionally critical domain.
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identified a novel homozygous frameshift variant (NM_001291746.4) REL:c.24del p.(Tyr9Ilefs*2). This variant introduces a very early premature stop codon."
    explanation: A further allele class, from the third reported patient, independently confirming that REL loss of function causes the disease.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "located in the essential acceptor splice site of exon 5 common to the 2 known REL isoforms"
    explanation: >-
      The second patient's allele, c.395-1G>A. It is the mirror of the index
      allele - acceptor rather than donor side of the same exon - and it affects
      both known REL isoforms.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The skipping of exon 5 is predicted to generate a frameshift and a premature stop codon at position 134 in the mRNA"
    explanation: >-
      The predicted consequence, and the contrast that matters: the acceptor-side
      lesion frameshifts, whereas the index patient's donor-side lesion produced an
      in-frame 18-residue deletion.
  downstream:
  - target: Absent c-Rel Protein
    causal_link_type: DIRECT
    description: >-
      Both alleles abolish or severely reduce c-Rel protein, which is the
      functional lesion rather than the transcript change itself.
- name: Absent c-Rel Protein
  biological_scale: MOLECULAR
  description: >-
    Both patients were shown by immunoblot of peripheral blood mononuclear cells to
    lack c-Rel protein - absent with no detectable truncation product in the index
    patient, severely reduced in the third. The third report adds an important
    specificity control: p65 (RelA) levels were preserved, so the lesion is
    subunit-selective rather than a general collapse of NF-kB. This is what makes
    the disease informative about c-Rel's non-redundant role in humans.
  genes:
  - preferred_term: REL
    term:
      id: hgnc:9954
      label: REL
  biological_processes:
  - preferred_term: canonical NF-kappaB signal transduction
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
  mechanism_confidence: ESTABLISHED
  notes: >-
    `modifier: LOSS_OF_FUNCTION` rather than `DECREASED` is deliberate here. The
    claim is qualitative - one subunit of the canonical NF-kB machinery is missing
    while the rest is intact, so the pathway's output is altered in composition,
    not merely reduced in amount. The preserved p65 is what licenses that reading.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "immunoblotting using an antibody specific to the protein's N-terminus demonstrated the absence of c-Rel protein in the patient's peripheral blood mononuclear cells (PBMCs) with no detectable truncation products, indicating that the mutation abrogates protein expression"
    explanation: Direct protein-level demonstration that the splice allele abolishes c-Rel, closing the gap between genotype and functional deficiency.
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Western blot analysis of peripheral blood mononuclear cells demonstrated a severe reduction of c Rel protein expression with preserved p65 levels, confirming its functional impact."
    explanation: Independent protein-level confirmation, and the preserved-p65 control establishing that the deficiency is subunit-selective.
  downstream:
  - target: Failed Transcription of c-Rel-Dependent Cytokine Genes
    causal_link_type: DIRECT
    description: >-
      c-Rel's function is transcriptional, so its absence is read out as failure to
      transcribe its promoter targets.
- name: Failed Transcription of c-Rel-Dependent Cytokine Genes
  biological_scale: MOLECULAR
  description: >-
    c-Rel binds the promoters of IL-2, IFN-gamma, IL-12, IL-21 and IL-23. That
    target set is not a random collection: IL-12 and IFN-gamma are the axis
    controlling macrophage activation against intracellular pathogens, IL-2 drives
    T-cell clonal expansion, and IL-21 is the principal T-follicular-helper signal
    for B-cell class switching and memory formation. The disease phenotype can be
    read almost directly off this promoter list, which is the strongest argument
    that the mechanism is correct despite the tiny patient number.
  biological_processes:
  - preferred_term: positive regulation of transcription by RNA polymerase II
    modifier: DECREASED
    term:
      id: GO:0045944
      label: positive regulation of transcription by RNA polymerase II
  - preferred_term: interleukin-12 production
    modifier: DECREASED
    term:
      id: GO:0032615
      label: interleukin-12 production
  mechanism_confidence: ESTABLISHED
  notes: >-
    This node was drafted as PROVISIONAL on the reasoning that c-Rel's promoter
    targets were established from prior immunology but had not been measured in
    patient cells. That was wrong: PMID:34623332 measures the output directly in a
    c-Rel-deficient patient, and the node is graded ESTABLISHED accordingly. The
    measurement is still n=1, but it is a direct measurement rather than an
    inference.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "c-Rel binds to the promoters of genes that encode cytokines important for immunity against infectious pathogens, including IL-2, IFN-γ, IL-12, IL-21, and IL-23."
    explanation: >-
      States the promoter target set this node depends on. This is the report's
      background statement of established c-Rel biology rather than a measurement
      in the patient; the measurement is the next two items.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Functional deficits of myeloid cells included the abolition of IL-12 and IL-23 production by conventional DC1s (cDC1s) and monocytes, but not cDC2s."
    explanation: >-
      Direct measurement of failed IL-12 and IL-23 output in patient cells - and
      the cell-type selectivity, which no promoter-binding argument predicts.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Functional deficits of lymphoid cells included reduced IL-2 production by naive T cells, correlating with low proliferation and survival rates and poor production of Th1, Th2, and Th17 cytokines by memory CD4+ T cells."
    explanation: Direct measurement of the lymphoid cytokine deficit in patient cells, linking reduced IL-2 to the observed proliferation and survival failure.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In naive CD4+ T cells, c-Rel is dispensable for early IL2 induction but contributes to later phases of IL2 expression."
    explanation: >-
      Refines the claim rather than simply supporting it - c-Rel is not required
      for IL-2 induction as such, only for sustaining it, which is why the T-cell
      defect is functional and partial rather than absolute.
  downstream:
  - target: Myeloid Antigen-Presenting Cell Failure
    causal_link_type: DIRECT
    description: >-
      Loss of IL-12/IL-23 output and of CD86 induction disables the myeloid arm of
      the response, independently of anything happening in lymphocytes.
  - target: Impaired T Cell Activation and Proliferation
    causal_link_type: DIRECT
    description: >-
      Loss of IL-2 transcription removes the principal autocrine proliferation
      signal for activated T cells.
  - target: Impaired B Cell Maturation and Class Switching
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Loss of IL-21, a T-cell-derived signal, acts on B cells through the helper
      compartment as well as through B-cell-intrinsic c-Rel.
  - target: Susceptibility to Intracellular and Opportunistic Pathogens
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Loss of IL-12 and IFN-gamma transcription disables the axis that activates
      macrophages against intracellular organisms.
- name: Myeloid Antigen-Presenting Cell Failure
  biological_scale: CELLULAR
  description: >-
    The arm that the phrase "combined immunodeficiency" hides. c-Rel is required in
    conventional type 1 dendritic cells and monocytes for IL-12 and IL-23
    production, and its loss abolishes that output - while cDC2s are spared. It is
    also required for CD86 induction on conventional dendritic cells, so the defect
    is not only cytokine secretion but antigen-presenting capacity itself. Since
    IL-12 from cDC1s is what licenses Th1 differentiation and IFN-gamma-dependent
    macrophage activation, this node explains the mycobacterial and intracellular
    susceptibility without needing to invoke a T-cell-intrinsic defect at all -
    though the entry models both, because both are measured.
  cell_types:
  - preferred_term: conventional dendritic cell
    term:
      id: CL:0000990
      label: conventional dendritic cell
  - preferred_term: monocyte
    term:
      id: CL:0000576
      label: monocyte
  biological_processes:
  - preferred_term: interleukin-23 production
    modifier: ABSENT
    term:
      id: GO:0032627
      label: interleukin-23 production
  - preferred_term: antigen processing and presentation
    modifier: DECREASED
    term:
      id: GO:0019882
      label: antigen processing and presentation
  mechanism_confidence: PROVISIONAL
  notes: >-
    Graded PROVISIONAL on patient number, not on the quality of the measurement.
    The experiments are direct and internally controlled (cDC1 affected, cDC2 not),
    but they were performed on one patient's cells.
  evidence:
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Functional deficits of myeloid cells included the abolition of IL-12 and IL-23 production by conventional DC1s (cDC1s) and monocytes, but not cDC2s."
    explanation: The measurement defining this node, including the cDC1/cDC2 dissociation that makes it a selective rather than global myeloid defect.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "c-Rel was also required for induction of CD86 expression on, and thus antigen-presenting cell function of, cDCs."
    explanation: Extends the defect from cytokine output to costimulation and antigen presentation.
  downstream:
  - target: Susceptibility to Intracellular and Opportunistic Pathogens
    causal_link_type: DIRECT
    description: >-
      Loss of cDC1-derived IL-12 removes the signal that licenses Th1 responses
      and IFN-gamma-dependent macrophage activation.
- name: Impaired T Cell Activation and Proliferation
  biological_scale: CELLULAR
  description: >-
    The index patient had numerically increased CD4+ and CD8+ T cells but reduced
    memory CD4+CD45RO+ cells and reduced proliferation to phytohaemagglutinin. The
    dissociation is informative: T cells are made and survive, but do not respond -
    a functional rather than a numerical T-cell defect, which is why the disease
    presents as combined immunodeficiency without lymphopenia.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: T cell proliferation
    modifier: DECREASED
    term:
      id: GO:0042098
      label: T cell proliferation
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had increased numbers of CD4+ and CD8+ T cells with decreased memory CD4+CD45RO+ T cells, and reduced proliferation to phytohemagglutinin (PHA)"
    explanation: >-
      The immunophenotyping and functional proliferation result underlying this
      node, from the index patient.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PBMCs from P did not proliferate, or only weakly proliferated, in vitro in response to any of the physiological"
    explanation: >-
      Independent replication of the proliferation defect in the second patient,
      and against PHYSIOLOGICAL antigens rather than a mitogen - the full sentence
      lists tuberculin, candidin, tetanus toxoid and CMV antigens, which ties the
      T-cell node directly to three of the patient's four infections. The snippet
      stops before "stimuli" because the cached text hyphenates that word across a
      line break.
- name: Impaired B Cell Maturation and Class Switching
  biological_scale: CELLULAR
  description: >-
    B-cell lymphopenia with impaired proliferation to CD40 ligand plus IL-21,
    reduced IgG and undetectable IgA, and non-protective tetanus and diphtheria
    titres despite boosters. Immunophenotyping at 9 years showed the compartment
    stuck at the naive stage - 85% naive CD19+IgD+CD27- B cells against a normal
    range of 47.3-77%, and 0.3% switched memory CD19+CD27+IgD- cells against a
    reference range of 10.0-30.4%. The failure of proliferation specifically to
    CD40L+IL-21 connects the cellular defect back to the c-Rel-dependent cytokine
    IL-21.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: memory B cell
    term:
      id: CL:0000787
      label: memory B cell
  biological_processes:
  - preferred_term: B cell proliferation
    modifier: DECREASED
    term:
      id: GO:0042100
      label: B cell proliferation
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He had B cell lymphopenia, impaired B cell proliferation upon stimulation with CD40 ligand + IL-21, reduced IgG and undetectable IgA levels, and non-protective titers to the tetanus and diphtheria vaccines despite booster vaccinations"
    explanation: >-
      The humoral phenotype, including the IL-21-specific proliferation defect that
      links it to the transcriptional node upstream. Single patient.
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "revealed a predominance of naïve CD19+IgD+CD27− B cells (85%; normal 47.3 – 77%) and reduced percentages of switched memory CD19+CD27+IgD− B cells (0.3%; reference range 10.0 – 30.4)"
    explanation: Quantifies the maturation block against reference ranges, showing the compartment arrested before class switching.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient's naive B cells displayed impaired MYC and BCL2L1 induction, compromising B cell survival and proliferation and preventing their differentiation into Ig-secreting plasmablasts."
    explanation: >-
      Identifies the B-cell-intrinsic transcriptional targets - MYC and BCL2L1 -
      whose failed induction blocks plasmablast differentiation, which is a
      different and more specific claim than the IL-21 route modelled upstream.
- name: Susceptibility to Intracellular and Opportunistic Pathogens
  biological_scale: ORGANISM
  description: >-
    The clinical endpoint. The index patient's organisms - Mycobacterium
    tuberculosis, Salmonella enterica, Cryptosporidium and cytomegalovirus - are
    precisely the set controlled by the IL-12/IFN-gamma axis and by cellular
    immunity, and the coherence of that list with c-Rel's promoter targets is the
    main evidence that the mechanism is right. The second patient's list is broader still - BCG
    disease, chronic mucocutaneous candidiasis, cryptosporidiosis, CMV disease and
    shingles - and adds a fungal axis that the IL-23/Th17 arm explains.
    Chronic cryptosporidiosis led on to cholangitis in BOTH fully described
    patients, the classic biliary complication of that organism in
    immunodeficiency, which makes it one of the better-replicated features here.
    The defect is graded rather than absolute, but the evidence for that is a
    DISSOCIATION rather than a uniform observation: the index patient tolerated
    live BCG, poliovirus and measles vaccines without sequelae, while the second
    patient developed disseminated BCG disease from the vaccine. Both are true, and
    the entry does not average them.
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study reports a homozygous mutation in REL abrogating c-Rel protein expression in a patient with combined immunodeficiency characterized by susceptibility to Mycobacterium tuberculosis, Salmonella, Cryptosporidium, and cytomegalovirus."
    explanation: The defining infectious susceptibility profile, stated as the report's headline finding.
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He received live vaccinations against poliovirus, measles, and Bacille Calmette-Guerin (BCG) without clinical sequelae."
    explanation: >-
      One half of the vaccine dissociation: the INDEX patient tolerated live
      vaccines, which is not the profile of severe combined immunodeficiency. Read
      with the next item, which reports the opposite outcome in the second patient.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "disseminated BCG disease following vaccination (BCG-osis), with bone, lung, and lymph node involvement"
    explanation: >-
      The other half, and the clinically decisive one: the second patient
      developed disseminated disease from the BCG vaccine itself. This is why the
      entry does not present live vaccines as tolerated in this disease.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we studied a child with BCG disease, CMC, cryptosporidiosis, CMV disease, and shingles"
    explanation: The second patient's infection profile, which is broader than the index patient's and adds the fungal axis.
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a third case is described of a 5-year-old Moroccan child with combined immunodeficiency presenting with chronic diarrhea and recurrent opportunistic infections"
    explanation: Independent replication of the chronic-diarrhoea-plus-opportunistic-infection presentation in an unrelated patient.
genetic:
- name: REL
  gene_term:
    preferred_term: REL
    term:
      id: hgnc:9954
      label: REL
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    REL encodes c-Rel, an NF-kB family transcription factor. Inheritance is
    autosomal recessive. THREE homozygous alleles are published:
    NM_002908.3:c.535+1G>A, a canonical DONOR splice-site variant after exon 5
    producing an in-frame 54-nucleotide deletion within the Rel homology domain via
    cryptic splice sites; c.395-1G>A, in the essential ACCEPTOR splice site of exon
    5 common to both known REL isoforms, where exon-5 skipping frameshifts to a
    premature stop at codon 134; and NM_001291746.4:c.24del p.(Tyr9Ilefs*2), a
    frameshift creating a very early premature stop. All three patients were from
    consanguineous families - Arabic, Moroccan and Moroccan respectively.
    The first two are worth reading together: the same exon, opposite splice
    boundaries, and different consequence classes (in-frame deletion versus
    frameshift), both ending in absent protein.

    Functional impact is loss of function for both alleles, demonstrated at protein
    level by immunoblot in each case rather than predicted from the variant class.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a homozygous mutation in the canonical donor splice-site after exon 5 of REL (NM_002908.3: c.535+1G>A) was considered the most likely pathogenic variant due to the known contribution of c-Rel in T and B cell activation and cytokine secretion"
    explanation: Names the index allele and the reasoning by which it was selected from 80 rare candidate variants.
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This report expands the mutational spectrum of REL and further supports the critical, non-redundant role of c-Rel in human immune homeostasis."
    explanation: The second report's own statement of what it adds - an expanded allelic spectrum and support for non-redundancy.
phenotypes:
- category: Immunologic
  name: Combined Immunodeficiency
  description: >-
    Impaired T-cell and B-cell function with preserved or increased T-cell numbers;
    a functional combined immunodeficiency rather than a lymphopenic one.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Combined immunodeficiency
    term:
      id: HP:0005387
      label: Combined immunodeficiency
  evidence:
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "immunodeficiency 92 (IMD92), an extremely rare autosomal recessive disorder due to c Rel deficiency that results from pathogenic variants of the REL gene"
    explanation: Names the entity and its immunodeficiency character; combined immunodeficiency is the presentation in both fully described patients.
- category: Immunologic
  name: Recurrent Mycobacterial Infection
  description: >-
    Femoral Mycobacterium tuberculosis osteomyelitis at 7 years despite prior BCG
    vaccination without sequelae - the signature of an IL-12/IFN-gamma axis defect.
  phenotype_term:
    preferred_term: Recurrent mycobacterial infections
    term:
      id: HP:0011274
      label: Recurrent mycobacterial infections
  notes: >-
    Reported in one patient. No frequency is asserted; with three cases in total,
    a FrequencyEnum band would be a statistical fiction.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Despite vaccination with BCG, he developed femoral Mycobacterium tuberculosis osteomyelitis at 7 years of age that was successfully treated with isoniazid, rifampin, pyrazinamide, and ethambutol."
    explanation: >-
      Documents the mycobacterial disease and its successful treatment. Graded
      PARTIAL because a single patient's infection establishes susceptibility as
      possible, not as a characteristic disease feature.
- category: Gastrointestinal
  name: Chronic Diarrhea
  description: >-
    Chronic diarrhoea associated with opportunistic enteric infection was the
    presenting illness in the index and third patients, in unrelated families.
    The second patient's gastrointestinal finding is chronic adenovirus and
    enterovirus replication rather than diarrhoea specifically.
  phenotype_term:
    preferred_term: Chronic diarrhea
    term:
      id: HP:0002028
      label: Chronic diarrhea
    temporality: CHRONIC
  notes: >-
    No frequency band is asserted, for the reason this entry states elsewhere: at
    n=3 a FrequencyEnum band is a statistical fiction. Two of three is in any case
    FREQUENT, not VERY_FREQUENT, and the description carries the information
    honestly without a band.
  evidence:
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a third case is described of a 5-year-old Moroccan child with combined immunodeficiency presenting with chronic diarrhea and recurrent opportunistic infections"
    explanation: Chronic diarrhoea as the presenting feature in the third patient, replicating the index presentation.
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At 30 months of age, he developed chronic diarrhea associated with multiple infections, including Salmonella enteritica, cytomegalovirus (CMV), and Cryptosporidium."
    explanation: The index patient's presenting chronic diarrhoea and its causative organisms.
- category: Hepatobiliary
  name: Sclerosing Cholangitis
  description: >-
    Sclerosing cholangitis with hepatomegaly, developing in the setting of chronic
    cryptosporidiosis - a complication of the infection rather than a primary
    consequence of c-Rel loss.
  phenotype_term:
    preferred_term: Sclerosing cholangitis
    term:
      id: HP:0030991
      label: Sclerosing cholangitis
  notes: >-
    Replicated across both fully described patients, in unrelated families, with
    the same aetiology - cryptosporidial biliary infection. That makes it one of
    the better-supported features in the entry, despite being secondary to a
    treatable infection rather than intrinsic to the mechanism.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the setting of chronic cryptosporidiosis, he developed hepatomegaly and sclerosing cholangitis."
    explanation: >-
      The index patient's cholangitis, explicitly attributed to the
      cryptosporidial infection rather than to c-Rel deficiency directly.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cholangitis due to C. parvum, esophageal candidiasis"
    explanation: >-
      Independent replication in the second patient, with the same organism -
      which is what upgrades this from a single-patient complication to a
      reproducible consequence of the immunodeficiency.
- category: Immunologic
  name: Decreased Circulating IgG
  description: Reduced IgG with undetectable IgA and failure to mount protective vaccine responses.
  phenotype_term:
    preferred_term: Decreased circulating IgG concentration
    term:
      id: HP:0004315
      label: Decreased circulating IgG concentration
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "reduced IgG and undetectable IgA levels, and non-protective titers to the tetanus and diphtheria vaccines despite booster vaccinations"
    explanation: The humoral deficiency and the functional vaccine-response failure. Single patient.
- category: Immunologic
  name: Decreased Circulating IgA
  description: Undetectable serum IgA in the index patient.
  phenotype_term:
    preferred_term: Decreased circulating IgA concentration
    term:
      id: HP:0002720
      label: Decreased circulating IgA concentration
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "reduced IgG and undetectable IgA levels, and non-protective titers to the tetanus and diphtheria vaccines despite booster vaccinations"
    explanation: Records the undetectable IgA. Single patient.
- category: Immunologic
  name: Disseminated BCG Disease
  description: >-
    Disseminated disease following BCG vaccination, with bone, lung and lymph node
    involvement, in the second patient. This is the entry's most consequential
    single clinical fact: the live attenuated vaccine itself caused disseminated
    mycobacterial disease.
  phenotype_term:
    preferred_term: BCGosis
    term:
      id: HP:0020087
      label: BCGosis
  notes: >-
    One of two BCG-vaccinated patients. The index patient tolerated BCG without
    sequelae. Both outcomes are recorded, and no frequency is asserted - see the
    discussion `imd92_bcg_dissociation`.
  evidence:
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "disseminated BCG disease following vaccination (BCG-osis), with bone, lung, and lymph node involvement"
    explanation: The disseminated BCG disease and its three sites, attributed to the vaccination.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disseminated BCG-osis with bone and lung lesions, cholangitis due to C. parvum, esophageal candidiasis"
    explanation: The imaging/clinical summary of the second patient's three defining complications.
- category: Immunologic
  name: Chronic Mucocutaneous Candidiasis
  description: >-
    Chronic mucocutaneous candidiasis including recurrent oesophagitis, in the
    second patient. Mechanistically this is the most informative of the second
    patient's infections: CMC is the canonical IL-17-axis phenotype, and c-Rel
    loss abolishes IL-23 production by cDC1s and impairs Th17 cytokine output by
    memory CD4+ T cells - so the fungal susceptibility follows the same
    promoter list as the mycobacterial one, one branch further down.
  phenotype_term:
    preferred_term: Chronic mucocutaneous candidiasis
    term:
      id: HP:0002728
      label: Chronic mucocutaneous candidiasis
    temporality: CHRONIC
  evidence:
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we studied a child with BCG disease, CMC, cryptosporidiosis, CMV disease, and shingles"
    explanation: Records CMC among the second patient's defining infections.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "poor production of Th1, Th2, and Th17 cytokines by memory CD4+ T cells"
    explanation: >-
      The measured Th17 deficit that connects the candidiasis to the entry's
      transcriptional node - the IL-23/Th17 branch of c-Rel's promoter list.
- category: Immunologic
  name: Severe Cytomegalovirus Infection
  description: Chronic CMV viraemia with recurrent fever in the second patient; CMV disease in the index patient.
  phenotype_term:
    preferred_term: Severe cytomegalovirus infection
    term:
      id: HP:0031692
      label: Severe cytomegalovirus infection
  evidence:
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we studied a child with BCG disease, CMC, cryptosporidiosis, CMV disease, and shingles"
    explanation: CMV disease in the second patient, replicating the index patient's CMV susceptibility.
- category: Immunologic
  name: Recurrent Viral Infections
  description: >-
    Recurrent oral HSV-1 lesions, an episode of thoracic shingles, and chronic
    gastrointestinal adenovirus and enterovirus replication in the second patient.
  phenotype_term:
    preferred_term: Recurrent viral infections
    term:
      id: HP:0004429
      label: Recurrent viral infections
    temporality: RECURRENT
  evidence:
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "P had various infections from early childhood onwards: CMC, including recurrent esophagitis; chronic CMV viremia with recurrent fever; recurrent oral herpes simplex virus 1 (HSV-1) lesions"
    explanation: The second patient's viral infection profile, listed with the chronicity and recurrence this phenotype records.
- category: Immunologic
  name: Reduced Memory Lymphocyte Subsets
  description: >-
    Deep immunophenotyping showed low frequencies of NK cells, Temra CD8+ T cells,
    memory CD4+ T cells including Th1, regulatory T cells and memory B cells, with
    other leukocyte subsets normal in count and proportion. The selectivity matters:
    this is a defect of differentiated and memory compartments, not a global
    lymphopenia.
  phenotype_term:
    preferred_term: Decreased proportion of memory B cells
    term:
      id: HP:0030374
      label: Decreased memory B cell proportion
  notes: >-
    The HPO binding captures only the memory-B-cell component. There is no single
    HP term for the pattern actually observed - a coordinated reduction across NK,
    Temra CD8, memory CD4/Th1, Treg and memory B compartments with other subsets
    normal - so the binding necessarily understates the finding, and the
    description carries the rest.
  evidence:
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient had low frequencies of NK, effector memory cells reexpressing CD45RA (Temra) CD8+ T cells, memory CD4+ T cells, including Th1 and Th1*, Tregs, and memory B cells, whereas the counts and proportions of other leukocyte subsets were normal."
    explanation: The immunophenotyping result, including the explicit statement that other subsets were normal, which makes the deficit selective.
- category: Skeletal
  name: Craniosynostosis
  description: >-
    Reported in the third patient only, and explicitly flagged by its authors as a
    newly reported feature. Whether it belongs to the disease at all is open.
  phenotype_term:
    preferred_term: Craniosynostosis
    term:
      id: HP:0001363
      label: Craniosynostosis
  notes: >-
    A single unreplicated observation in a consanguineous child, where a second
    recessive condition is a live alternative explanation. Recorded so it can be
    checked against future cases, not asserted as a disease feature. See the
    discussion `imd92_novel_features_third_patient`.
  evidence:
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "alongside newly reported features including craniosynostosis, language delay, and epilepsy"
    explanation: >-
      Graded PARTIAL. The authors describe these as newly reported; one patient in
      a consanguineous family is not sufficient to attribute a non-immunological
      feature to REL.
- category: Neurologic
  name: Epilepsy
  description: Reported in the third patient only, alongside language delay, and unreplicated.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  notes: >-
    As for craniosynostosis - single unreplicated report in a consanguineous
    child.
  evidence:
  - reference: PMID:42117340
    reference_title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "alongside newly reported features including craniosynostosis, language delay, and epilepsy"
    explanation: Same single-patient limitation as craniosynostosis.
treatments:
- name: Immunoglobulin Replacement
  description: >-
    The supportive standard for a combined immunodeficiency with humoral failure.
    The index patient received intravenous immunoglobulin. This is the management
    actually reported; it is not disease-specific and no outcome data exist for it
    in IMD92.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: immunoglobulin therapy
    term:
      id: NCIT:C62710
      label: Immunoglobulin Therapy
  target_mechanisms:
  - target: Impaired B Cell Maturation and Class Switching
    description: >-
      Replacement immunoglobulin substitutes for the antibody the patient's own
      arrested B-cell compartment cannot make.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He is currently treated with intravenous immunoglobulin and prophylactic antibiotics while undergoing evaluation for hematopoietic stem cell transplantation."
    explanation: >-
      Reports the treatment given. It documents practice in one patient, with no
      outcome measure, so it establishes what was done rather than that it works.
- name: Antimicrobial Prophylaxis
  description: >-
    Prophylactic antibiotics alongside immunoglobulin replacement in the index
    patient. Split from the immunoglobulin entry so that the modality and the
    mechanism it targets are separately queryable - the two interventions address
    different arms of the defect.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
  target_mechanisms:
  - target: Susceptibility to Intracellular and Opportunistic Pathogens
    description: >-
      Prophylaxis substitutes for the cellular immunity the patient cannot
      mount, rather than correcting it.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He is currently treated with intravenous immunoglobulin and prophylactic antibiotics while undergoing evaluation for hematopoietic stem cell transplantation."
    explanation: The same sentence documents both arms of the supportive regimen; it reports practice in one patient with no outcome measure.
- name: Hematopoietic Stem Cell Transplantation
  description: >-
    The curative option, and it has been done. The second patient was transplanted
    in 2017 and her infectious phenotypes were cured. The index patient was under
    evaluation for transplantation at the time of his report.
    The cure is worth more to this entry than a treatment outcome. Because HSCT
    replaces only the haematopoietic compartment, simultaneous correction of the
    immunological and the infectious phenotypes is a rescue experiment: it
    establishes that the disease is caused by intrinsic defects of leukocytes
    rather than by anything c-Rel does elsewhere. That is direct support for the
    pathograph modelled above, not just for the treatment.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  target_mechanisms:
  - target: Absent c-Rel Protein
    description: >-
      Replacing the haematopoietic compartment with donor cells restores c-Rel
      expression in the lineages where it is required.
  evidence:
  - reference: PMID:31103457
    reference_title: Combined immunodeficiency in a patient with c-Rel deficiency.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "while undergoing evaluation for hematopoietic stem cell transplantation"
    explanation: >-
      Graded PARTIAL - it establishes that transplantation was considered
      clinically appropriate for the index patient, but reports an evaluation
      rather than an outcome. The next item reports the outcome.
  - reference: PMID:34623332
    reference_title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The simultaneous correction of the immunological and infectious phenotypes by HSCT confirmed that the patient’s immunodeficiency was caused by severe intrinsic defects of leukocytes."
    explanation: >-
      The cure, and the inference the authors draw from it. Because HSCT replaces
      only haematopoietic cells, correcting both phenotypes at once is rescue
      evidence that the disease is leukocyte-intrinsic - which supports the whole
      pathograph, not only this treatment.
animal_models:
- name: Rel-knockout mouse
  species: Mouse
  genotype: c-rel-/- (germline inactivation)
  publication: PMID:7649478
  description: >-
    The germline c-rel knockout mouse, described in 1995 - nearly a quarter of a
    century before the first human patient, and the reason c-Rel was an immediate
    candidate when that patient was sequenced.
  modeled_mechanisms:
  - target: Impaired T Cell Activation and Proliferation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Rel-/- mice develop all haemopoietic lineages normally but have impaired
      humoral immunity and mature B and T cells unresponsive to most mitogens -
      the same functional-rather-than-numerical pattern seen in the human patients.
      The model additionally locates the defect: exogenous IL-2 restores T-cell but
      not B-cell proliferation, so c-Rel regulates different required genes in the
      two lineages.
    limitations: >-
      A mouse null against human alleles that also abolish protein, so the genotype
      match is good - but the mouse phenotype is described as a mitogenic-response
      defect rather than as susceptibility to mycobacteria and opportunistic
      organisms, and the cDC1-selective IL-12 defect that dominates the human
      disease was not part of the original murine characterisation.
    readouts:
    - name: T cell proliferation after exogenous IL-2
      target: Impaired T Cell Activation and Proliferation
      direction: RESTORED
      interpretation: >-
        IL-2 rescues the T-cell but not the B-cell proliferative defect, dissecting
        the lineage-specific requirement for c-Rel.
      evidence:
      - reference: PMID:7649478
        reference_title: "Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The ability of exogenous interleukin-2 to restore T Cell, but not B cell, proliferation indicates that Rel regulates the expression of different genes in B and T cells that are crucial for cell division and immune function."
        explanation: The rescue result and the lineage dissociation it establishes.
    evidence:
    - reference: PMID:7649478
      reference_title: "Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In mice with an inactivated c-rel gene, whereas development of cells from all hemopoietic lineages appeared normal, humoral immunity was impaired and mature B and T cells were found to be unresponsive to most mitogenic stimuli."
      explanation: >-
        Establishes the model's core phenotype and, importantly, that lineage
        DEVELOPMENT is normal - the same functional-not-numerical signature as the
        human disease.
  - target: Failed Transcription of c-Rel-Dependent Cytokine Genes
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Rel-/- T cells show impaired cytokine production with normal surface
      activation markers, confirming that the lesion is transcriptional rather than
      a failure of activation.
    limitations: >-
      The murine work also shows c-Rel acting as a REPRESSOR in another cell type -
      LPS-stimulated Rel-/- macrophages overproduce GM-CSF - so a purely
      loss-of-activation model is too simple, and this entry's transcriptional node
      does not attempt to capture the repressor role.
    evidence:
    - reference: PMID:8622948
      reference_title: "Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The expression of cell surface markers including the interleukin 2 receptor alpha (IL-2R alpha) chain (CD25), CD69 and L-selectin (CD62) is normal in mitogen-activated Rel-/- T cells, but cytokine production is impaired."
      explanation: Separates the transcriptional defect from a failure of activation, since surface activation markers are induced normally.
    - reference: PMID:8622948
      reference_title: "Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In contrast to mitogen-activated Rel-/- T cells, lipopolysaccharide-stimulated Rel-/- macrophages produce higher than normal levels of GM-CSF."
      explanation: >-
        Graded PARTIAL because it complicates rather than supports the node -
        c-Rel represses as well as activates depending on cell type, which the
        entry's transcriptional node does not model.
discussions:
- discussion_id: imd92_evidence_base_is_three_cases
  kind: KNOWLEDGE_GAP
  attaches_to:
  - disease#Immunodeficiency 92
  prompt: >-
    How much of this entry would survive a fourth and fifth patient?
  rationale: >-
    Three patients have been reported in total, and only two in enough detail to
    curate. Every phenotype except chronic diarrhoea rests on a single individual.
    The mechanism is nonetheless unusually credible for such a small series, for
    two reasons beyond coherence with c-Rel's promoter targets. Several features
    DO replicate across unrelated families - cryptosporidial cholangitis, the
    proliferation defect, CMV susceptibility. And the second patient's cure by
    HSCT is a rescue result: correcting both the immunological and the infectious
    phenotypes by replacing only the haematopoietic compartment establishes the
    disease as leukocyte-intrinsic. Readers should treat the pathophysiology chain
    as well-motivated and the phenotype frequencies as essentially unknown. This
    gap is attached to the disease as a whole because it conditions every claim in
    the entry rather than any one of them.
- discussion_id: imd92_novel_features_third_patient
  kind: OPEN_QUESTION
  attaches_to:
  - phenotypes#Craniosynostosis
  - phenotypes#Epilepsy
  prompt: >-
    Are craniosynostosis, language delay and epilepsy part of IMD92, or
    coincidental findings in one consanguineous child?
  rationale: >-
    The third patient's report describes these as newly reported features. Two
    things argue for caution. There is no known role for c-Rel in cranial suture
    fusion or in neuronal excitability that would predict them, and the patient is
    from a consanguineous family, which is exactly the setting in which a second
    unrelated recessive disorder is likeliest. Recording them as PARTIAL evidence
    with an explicit note is the honest handling: they should be checked against
    the next reported patient rather than either dismissed or absorbed into the
    phenotype.
- discussion_id: imd92_cdc1_versus_cdc2_selectivity
  kind: OPEN_QUESTION
  attaches_to:
  - pathophysiology#Myeloid Antigen-Presenting Cell Failure
  prompt: >-
    Why is IL-12/IL-23 production abolished in cDC1s and monocytes but preserved in
    cDC2s?
  rationale: >-
    This is the sharpest result in the disease and the least explained. Both
    dendritic-cell subsets express c-Rel and both make IL-12 family cytokines, so a
    simple "c-Rel binds the IL12B promoter" account predicts both should fail.
    Candidate explanations - a subset-specific difference in NF-kB subunit
    redundancy, differing dependence on c-Rel versus RelA at the same promoters, or
    a difference in the upstream signals each subset uses - have not been
    distinguished. It matters beyond this disease: cDC1 and cDC2 are being targeted
    separately in vaccine and cancer immunotherapy design, and a natural human
    knockout that separates them is unusually informative.
- discussion_id: imd92_bcg_dissociation
  kind: OPEN_QUESTION
  attaches_to:
  - pathophysiology#Susceptibility to Intracellular and Opportunistic Pathogens
  - phenotypes#Disseminated BCG Disease
  prompt: >-
    Why did BCG vaccination cause disseminated disease in one c-Rel-deficient
    patient and no sequelae in another?
  rationale: >-
    Both fully described patients were BCG-vaccinated. The index patient had no
    clinical sequelae and developed femoral M. tuberculosis osteomyelitis only
    years later; the second patient developed disseminated BCG disease from the
    vaccine, with bone, lung and lymph node involvement. That dissociation is the
    strongest available evidence that the cellular defect is graded rather than
    absolute - the grading now has observed variance across patients instead of
    being inferred from a single tolerant case.
    What explains the variance is unknown. The alleles differ (an in-frame
    18-residue deletion versus a frameshift at codon 134), so residual protein
    function is one candidate; redundancy among NF-kB subunits differing by
    individual, host genetic modifiers, and BCG strain or dose are others. Two
    patients cannot separate them.
    The practical stake is immediate and this entry does not hedge it: live BCG has
    caused disseminated disease in one of the two vaccinated c-Rel-deficient
    patients reported, so nothing here supports treating live vaccines as safe in
    this disease.
references:
- reference: PMID:31103457
  title: Combined immunodeficiency in a patient with c-Rel deficiency.
- reference: PMID:42117340
  title: A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
- reference: PMID:34623332
  title: Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
- reference: PMID:7649478
  title: "Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression."
- reference: PMID:8622948
  title: "Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor."
📚

References & Deep Research

References

5
Combined immunodeficiency in a patient with c-Rel deficiency.
No top-level findings curated for this source.
A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing Immunodeficiency-92 With Profound c-Rel Deficiency.
No top-level findings curated for this source.
Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents.
No top-level findings curated for this source.
Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression.
No top-level findings curated for this source.
Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor.
No top-level findings curated for this source.

Deep Research

1
OpenScientist
Immunodeficiency 92 (IMD92): Comprehensive Disease Characteristics Report
openscientist-autonomous 12 citations 2026-08-28T10:55:18.738070

Immunodeficiency 92 (IMD92): Comprehensive Disease Characteristics Report

Disease: Immunodeficiency 92 (IMD92) Cause: Biallelic loss-of-function variants in REL (c-Rel deficiency) Category: Mendelian, autosomal recessive OMIM: #619652 | MONDO: MONDO:0030498 | Gene: REL (HGNC:9954, NCBI Gene 5966, MIM *164910)


Summary

Immunodeficiency 92 (IMD92) is an ultra-rare autosomal recessive combined immunodeficiency (CID) caused by biallelic (homozygous) loss-of-function variants in REL, the gene encoding c-Rel, one of the five members of the NF-κB transcription-factor family and a core subunit of the canonical NF-κB pathway. c-Rel is selectively expressed in lymphoid and myeloid cells, where it controls the transcriptional programs required for effective adaptive and innate immunity. When c-Rel is absent, patients develop early-childhood susceptibility to a broad spectrum of viral, bacterial, fungal, and parasitic pathogens, including intracellular organisms such as Mycobacterium tuberculosis, Salmonella, Cryptosporidium, and cytomegalovirus (CMV), typically accompanied by hypogammaglobulinemia and impaired T- and B-cell function.

As of 2026, IMD92 remains exceedingly rare — only three patients from three consanguineous families have been reported worldwide (Beaussant-Cohen 2019; Lévy 2021; El-Hamri 2026). Each patient carried a distinct homozygous REL null allele: a canonical splice-site variant (c.535+1G>A), an undefined loss-of-function allele, and a frameshift (c.24del, p.Tyr9Ilefs*2), respectively. Functional studies across these patients converge on a unified mechanism: c-Rel loss simultaneously cripples myeloid immunity (abolished IL-12/IL-23 production by conventional type-1 dendritic cells [cDC1s] and monocytes; impaired CD86-dependent antigen presentation) and lymphoid immunity (reduced regulatory T cells [Tregs], memory CD4+/CD8+ T cells, NK cells, and memory B cells; defective naive-T-cell IL-2 production; impaired B-cell proliferation and antibody production).

The human phenotype is faithfully recapitulated by the Rel-knockout mouse, which shows impaired humoral immunity, mitogen-unresponsive B and T lymphocytes, and an IL-2–dependent T-cell proliferation defect — establishing a robust, evolutionarily conserved genotype-phenotype relationship. Management follows general combined-immunodeficiency standards: immunoglobulin replacement, anti-infective prophylaxis, and allogeneic hematopoietic stem cell transplantation (HSCT) as the rational curative approach. This report compiles the available evidence across all 15 requested disease-characteristic domains, explicitly flagging the many areas where data do not yet exist for this newly described, ultra-rare disorder.


Key Findings

Finding 1 — IMD92 is an autosomal recessive combined immunodeficiency caused by biallelic REL loss-of-function (c-Rel deficiency)

IMD92 (OMIM #619652) is defined by biallelic loss-of-function variants in REL (chromosome 2p16.1), which encodes the NF-κB subunit c-Rel. The gene identifiers are HGNC:9954, NCBI Gene 5966, and MIM *164910. The index patient carried a homozygous REL null mutation abrogating c-Rel protein expression (Beaussant-Cohen 2019, PMID: 31103457). The most recently reported patient (2026) carried a homozygous frameshift variant, NM_001291746.4:REL:c.24del, p.(Tyr9Ilefs*2), with Western blotting confirming severe c-Rel reduction while p65/RelA was preserved (El-Hamri 2026, PMID: 42117340). The 2026 report states the disorder is "immunodeficiency 92 (IMD92), an extremely rare autosomal recessive disorder due to c Rel deficiency that results from pathogenic variants of the REL gene" and "identified a novel homozygous frameshift variant (NM_001291746.4) REL:c.24del p.(Tyr9Ilefs*2)." Only three patients have been reported worldwide, defining IMD92 as an ultra-rare Mendelian inborn error of immunity.

Finding 2 — Phenotype: broad susceptibility to intracellular/opportunistic pathogens, chronic diarrhea, and possible neuro-developmental features

The index patient presented with a combined immunodeficiency characterized by susceptibility to intracellular and opportunistic pathogens — Mycobacterium tuberculosis, Salmonella, Cryptosporidium, and CMV (Beaussant-Cohen 2019, PMID: 31103457). The third patient — a 5-year-old Moroccan child from a consanguineous family — was described as "a 5-year-old Moroccan child with combined immunodeficiency presenting with chronic diarrhea and recurrent opportunistic infections, alongside newly reported features including craniosynostosis, language delay, and epilepsy" (El-Hamri 2026, PMID: 42117340). Whether the neuro-developmental and craniofacial features are core to IMD92 or incidental (e.g., related to consanguinity or a second variant) remains uncertain given the tiny patient number.

Finding 3 — Mechanism: c-Rel is a canonical NF-κB subunit controlling Treg development, T-cell effector function, and myeloid cytokine output

c-Rel is one of five NF-κB family members and, per El-Hamri 2026, "c Rel is a key actor of the NF-κB pathway with major implications in the immune response" (PMID: 42117340; see also PMID: 42261849). NF-κB transcription factors have "essential functions... in modulating Treg development and function, with some of these mechanistic insights confirmed by recent studies analyzing Treg cells from patients harboring point mutations in the genes encoding NF-κB proteins" (PMID: 35672519). Mouse studies show Rel-deficient T cells have "defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor" (PMID: 8622948), and c-Rel drives IL-2/IFN-γ transcription while promoting FOXP3/Treg programs (PMID: 41410797).

Finding 4 — Index patient: homozygous REL splice variant c.535+1G>A with detailed combined immunophenotype

Beaussant-Cohen 2019 (PMID: 31103457; PMC6688935) described a male proband homozygous for a canonical donor splice-site variant REL NM_002908.3:c.535+1G>A (chr2:61144153 G/A, GRCh37), absent from gnomAD and 1000 Genomes, and heterozygous in unaffected parents and a healthy brother (consistent with autosomal recessive segregation). The mutant transcript uses cryptic splice sites and lacks 54 nucleotides encoding 18 residues within the Rel homology domain, abrogating c-Rel protein. The immunophenotype (age 6) is summarized in the table below.

Parameter Finding Reference range
WBC Leukocytosis / lymphocytosis / thrombocytosis
CD4+ / CD8+ T cells Increased
Memory CD4+CD45RO+ T cells Decreased
PHA proliferation 47.3% (reduced)
B cells B-cell lymphopenia
B-cell proliferation (CD40L+IL-21) 6.4% (impaired)
IgG 150 mg/dL 650–1150
IgM 150 mg/dL
IgA Undetectable
Anti-diphtheria titer 0.015 IU/mL (non-protective, despite boosters)
Switched memory B cells 0.3% 10.0–30.4%

The patient was treated with IVIG plus antibiotic prophylaxis and evaluated for HSCT. The dual role of c-Rel in the immune response underlies this combined immunophenotype ("c Rel is a key actor of the NF-κB pathway with major implications in the immune response", PMID: 42117340).

Finding 5 — Second patient (Lévy 2021, JCI): the myeloid+lymphoid mechanism defined

Lévy et al. 2021 (J Clin Invest 131(17):e150143; PMID: 34623332; Casanova/Puel laboratory) "studied a child with severe viral, bacterial, fungal, and parasitic diseases, who was homozygous for a loss-of-function mutation of REL, encoding c-Rel, which is selectively expressed in lymphoid and myeloid cells." This study delineated the dual mechanism:

  • Myeloid defects: "Functional deficits of myeloid cells included the abolition of IL-12 and IL-23 production by conventional DC1s (cDC1s) and monocytes, but not cDC2s." c-Rel was also required for CD86 induction and the antigen-presenting function of conventional dendritic cells.
  • Lymphoid defects: "low frequencies of NK, effector memory cells reexpressing CD45RA (Temra) CD8+ T cells, memory CD4+ T cells, including Th1 and Th1*, Tregs, and memory B cells." Naive T cells produced reduced IL-2, impairing proliferation/survival, with poor Th1/Th2/Th17 cytokine output by memory CD4+ T cells.

The patient was from Casablanca, Morocco.

Finding 6 — Rel-knockout mice faithfully recapitulate the human IMD92 immune defect

Rel-null mice show normal development of all hematopoietic lineages but "humoral immunity was impaired and mature B and T cells were found to be unresponsive to most mitogenic stimuli" (Köntgen et al. 1995, Genes Dev, PMID: 7649478). Critically, "the ability of exogenous interleukin-2 to restore T cell, but not B cell, proliferation indicates that Rel regulates the expression of different genes in B and T cells." Gerondakis et al. 1996 independently confirmed that "mice lacking Rel are defective in mitogenic activation of B and T lymphocytes and display impaired humoral immunity" (PMID: 8622948). These murine phenotypes match the human patients' impaired PHA/T-cell proliferation, hypogammaglobulinemia, and IL-2 deficit, establishing a conserved genotype–phenotype mechanism.


Mechanistic Model / Interpretation

The pathophysiology of IMD92 flows directly from loss of the c-Rel transcription factor in immune cells:

   Biallelic REL LOF (c.535+1G>A / c.24del / other null)
        │
        ▼
     Absent / severely reduced c-Rel protein
       (Rel homology domain disrupted; p65/RelA preserved)
        │
┌───────────────┴────────────────┐
▼                                 ▼
   MYELOID ARM                       LYMPHOID ARM
   • cDC1 + monocyte                 • ↓ naive-T IL-2 → poor
     IL-12/IL-23 abolished             proliferation/survival
   • ↓ CD86 induction →              • ↓ Tregs (FOXP3 program)
     impaired antigen                • ↓ memory CD4+ (Th1/Th1*),
     presentation                      CD8+ Temra, NK cells
│                             • ↓ memory/switched B cells,
│                               impaired antibody production
└───────────────┬────────────────┘
        ▼
Defective Th1 / intracellular-pathogen immunity
+ hypogammaglobulinemia + poor vaccine responses
        │
        ▼
   Combined immunodeficiency: susceptibility to viral, bacterial,
   fungal, parasitic (M. tuberculosis, Salmonella, Cryptosporidium,
   CMV) infections; chronic diarrhea; early childhood onset

Upstream vs downstream: The upstream lesion is transcriptional — loss of c-Rel–dependent gene programs. Downstream consequences are the failure of key cytokine axes, most importantly the IL-12/IL-23 → Th1/IFN-γ axis (explaining mycobacterial and intracellular-pathogen susceptibility) and the IL-2 → T-cell expansion axis — plus impaired humoral immunity. The myeloid defect (antigen-presenting-cell cytokine failure) and the lymphoid defect (intrinsic T/B-cell dysfunction) are additive, producing a broader infection spectrum than a purely lymphoid CID.

Ontology term suggestions: - Gene/Protein: REL / c-Rel (HGNC:9954, UniProt Q04864) - GO biological process: GO:0038061 (canonical NF-κB signal transduction), GO:0042110 (T cell activation), GO:0050852 (T cell receptor signaling pathway), GO:0045066 (regulatory T cell differentiation), GO:0032609 (IFN-γ production), GO:0032735 (positive regulation of IL-12 production), GO:0032747 (positive regulation of IL-23 production) - GO cellular component: GO:0005634 (nucleus), transcription regulator complex - CL cell types: CL:0000451 (dendritic cell), CL:0002399 (CD141-positive/cDC1), CL:0000576 (monocyte), CL:0000815 (regulatory T cell), CL:0000623 (natural killer cell), CL:0000787 (memory B cell), CL:0000897 (memory CD4+ T cell) - UBERON: UBERON:0002371 (bone marrow), UBERON:0002106 (spleen), UBERON:0002509 (mesenteric lymph node), UBERON:0002405 (immune system), UBERON:0000059 (large intestine — chronic diarrhea) - CHEBI (mediators/therapeutics): interleukin-2, interleukin-12, interleukin-23, interferon-gamma, immunoglobulin G - MONDO: MONDO:0030498


Section-by-Section Report

1. Disease Information

IMD92 is an autosomal recessive combined immunodeficiency due to c-Rel deficiency. Key identifiers: OMIM #619652; MONDO:0030498; gene REL (MIM *164910). Orphanet, ICD-10/ICD-11, and MeSH do not yet carry a dedicated code for this ultra-rare entity; it falls under the broad category of combined immunodeficiencies (ICD-10 D81; ICD-11 4A01). Synonyms: c-Rel deficiency; immunodeficiency due to c-Rel deficiency; REL-deficiency combined immunodeficiency. Information is derived from individual patient case reports (three probands) plus aggregated disease-level curation (OMIM) and model-organism data — not from EHR/registry aggregation.

2. Etiology

The sole established cause is genetic: biallelic (homozygous) loss-of-function variants in REL. There are no known environmental, infectious, or acquired causes of the underlying deficiency (infections are consequences, not causes). Genetic risk factor: homozygosity for a REL null allele; consanguinity is a major enabling factor — the index (Kuwaiti) and third (Moroccan) families were consanguineous. No susceptibility loci, modifier genes, or protective alleles have been identified (patient numbers too small). No gene–environment interactions have been characterized. Heterozygous carriers appear healthy (parents/siblings were unaffected carriers), consistent with recessive loss-of-function.

3. Phenotypes

Phenotype Type HPO suggestion Notes / frequency
Recurrent/opportunistic infections Clinical HP:0002719 (recurrent infections) All patients
Susceptibility to mycobacteria Clinical HP:0032266 (atypical mycobacterial infection) Index patient
CMV / viral disease Clinical HP:0011947 Index + patient 2
Chronic diarrhea Clinical/GI HP:0002028 Patient 3; Cryptosporidium in index
Decreased IgG (hypogammaglobulinemia) Lab HP:0004315 IgG 150 mg/dL (index)
Decreased IgA Lab HP:0002850 Undetectable (index)
Poor specific antibody response Lab HP:0005387 Non-protective diphtheria/tetanus titers
Decreased switched memory B cells Lab HP:0031381 0.3% (ref 10–30%)
Reduced T-cell proliferation Lab abnormal T-cell proliferation PHA 47.3%
Decreased Tregs / NK / memory T cells Lab HP:0410358, HP:0040218 Patient 2
Craniosynostosis Physical HP:0001363 Patient 3 only (uncertain relatedness)
Language delay Behavioral/neuro HP:0000750 Patient 3 only
Epilepsy Clinical/neuro HP:0001250 Patient 3 only

Onset: early childhood (index evaluated at age 6; patient 3 presented at age 5), likely reflecting a congenital immune defect. Severity: severe combined-immunodeficiency phenotype. Progression: chronic/lifelong without curative treatment. Quality of life: substantial impact — recurrent infections, chronic diarrhea, and lifelong immunoglobulin/prophylaxis requirements; formal QoL instruments have not been applied to this ultra-rare cohort.

4. Genetic / Molecular Information

Causal gene: REL (chr2p16.1; HGNC:9954; NCBI Gene 5966; MIM *164910; UniProt Q04864). Reported pathogenic variants:

Patient Variant (nomenclature) Type Population frequency Consequence
Index (Beaussant-Cohen 2019) NM_002908.3:c.535+1G>A Canonical splice donor Absent from gnomAD & 1000G Cryptic splicing; loss of 18 aa in Rel homology domain; no protein
Patient 2 (Lévy 2021) Homozygous REL LOF Loss-of-function Rare/absent Abolished c-Rel; loss of function
Patient 3 (El-Hamri 2026) NM_001291746.4:c.24del, p.(Tyr9Ilefs*2) Frameshift Rare/absent Severe c-Rel reduction; p65/RelA preserved

All variants are germline, homozygous, loss-of-function (ACMG: pathogenic). No somatic or gain-of-function IMD92 alleles exist. Note the mechanistic contrast: REL 3′-truncations and amplifications are recurrent oncogenic gain-of-function events in lymphoma (PMID: 34695199) — the opposite of the loss-of-function that causes IMD92. No modifier genes, epigenetic drivers, or chromosomal abnormalities have been described for IMD92.

5. Environmental Information

No environmental toxins, radiation, or occupational exposures contribute to disease causation. Infectious agents are downstream consequences, not triggers: Mycobacterium tuberculosis, Salmonella spp., Cryptosporidium spp., cytomegalovirus, and (in patient 2) fungal and parasitic pathogens. Consanguinity (a demographic/social factor) is the principal enabling condition for homozygosity.

6. Mechanism / Pathophysiology

Molecular pathway: canonical NF-κB signaling (c-Rel–containing dimers). Cellular processes: T-cell activation/proliferation, Treg differentiation, dendritic-cell/monocyte cytokine production and antigen presentation, B-cell activation and antibody production. Protein dysfunction: loss of function via truncation/splice disruption of the Rel homology domain → absent DNA-binding transcription factor (p65/RelA preserved). Immune involvement: combined (myeloid + lymphoid) immunodeficiency. Key downstream axes: IL-12/IL-23 → Th1/IFN-γ (abolished in cDC1s/monocytes) and IL-2 → T-cell expansion (reduced in naive T cells). Molecular profiling of IMD92 has been limited to targeted immunophenotyping and Western blot; no patient transcriptomic/proteomic/metabolomic datasets are published. See the Mechanistic Model section above for the full causal chain and ontology terms.

7. Anatomical Structures Affected

Primary system: the immune/hematolymphoid system (UBERON:0002405). Organs/tissues: bone marrow (UBERON:0002371), spleen, lymph nodes, and the thymus-derived T-cell compartment; the gastrointestinal tract (UBERON:0000059, large intestine) via chronic diarrhea/Cryptosporidium. Cell populations: cDC1 (CL:0002399), monocytes (CL:0000576), regulatory T cells (CL:0000815), memory CD4+/CD8+ T cells, NK cells (CL:0000623), memory/switched B cells (CL:0000787). Subcellular: nucleus (GO:0005634) — the site of c-Rel transcriptional activity. In patient 3, additional structures (cranial sutures — craniosynostosis; CNS — epilepsy/language delay) were reported, though their causal link to REL is unconfirmed. Involvement is systemic/bilateral.

8. Temporal Development

Onset: pediatric/early childhood (ages 5–6 at presentation), likely a congenital immune defect manifesting with first infections. Onset pattern: chronic/insidious with recurrent acute infectious episodes. Progression: chronic and lifelong without curative HSCT; progressive infectious morbidity. Critical period: early diagnosis and definitive treatment (HSCT) before accumulation of infection-related organ damage is the key therapeutic window. No spontaneous remission occurs.

9. Inheritance and Population

Inheritance: autosomal recessive. Penetrance: appears complete in biallelic individuals; carriers unaffected. Expressivity: variable — patient 3 exhibited extra neuro-developmental features. Epidemiology: ultra-rare — only 3 reported patients worldwide (as of 2026); prevalence/incidence not calculable. Founder effects / carrier frequency: unknown; REL LOF alleles are individually private and absent/rare in gnomAD. Consanguinity is central (Kuwaiti and Moroccan consanguineous families). Demographics: reported patients of Middle Eastern (Kuwaiti) and North African (Moroccan) origin; no established sex bias (numbers too small). Genetic anticipation and mosaicism: not applicable/not reported.

10. Diagnostics

Laboratory: immunoglobulin panel (hypogammaglobulinemia — low IgG/IgM, absent IgA); lymphocyte subset flow cytometry (memory B/T, Treg, NK enumeration); specific antibody titers (post-vaccination diphtheria/tetanus — non-protective); lymphocyte proliferation assays (PHA/mitogen, anti-CD3/CD28, CD40L+IL-21). Functional immunology: IL-12/IL-23 production by monocyte-derived/conventional DCs; IL-2 production by naive T cells; c-Rel Western blot (absent protein with preserved p65/RelA is characteristic). Genetic testing (definitive): whole-exome or whole-genome sequencing identifying biallelic REL LOF, confirmed by Sanger sequencing and family segregation. Inborn-errors-of-immunity/CID gene panels that include REL are appropriate. Differential diagnosis: other CIDs and NF-κB-pathway inborn errors of immunity — NFKB1 haploinsufficiency/CVID (PMID: 34473196), RELA haploinsufficiency/dominant-negative disease (PMID: 42261849, PMID: 40876844), RelB deficiency (PMID: 42261849), A20/TNFAIP3 haploinsufficiency (PMID: 34808442) — distinguished by inheritance pattern and immunophenotype. Screening: not on newborn screening panels; cascade/carrier testing feasible within affected families once the variant is known.

11. Outcome / Prognosis

Formal survival statistics do not exist for this 3-patient cohort. By analogy to other combined immunodeficiencies, untreated IMD92 carries high infection-related morbidity and mortality; with immunoglobulin replacement and anti-infective prophylaxis, acute risk is reduced, and allogeneic HSCT offers potential cure. Complications include recurrent/opportunistic infections, chronic diarrhea with failure to thrive, and (in patient 3) neurological morbidity. Prognostic factors: timeliness of diagnosis and access to HSCT; degree of pre-transplant infectious organ damage. No validated prognostic biomarkers exist beyond the immunophenotype.

12. Treatment

Supportive/standard-of-care (from index patient): immunoglobulin (IVIG) replacement plus antibiotic/anti-infective prophylaxis. Curative: allogeneic hematopoietic stem cell transplantation (HSCT) — the rational definitive therapy for a hematopoietic-intrinsic combined immunodeficiency; the index patient was evaluated for HSCT. Directed anti-infective therapy is used for specific pathogens (anti-mycobacterial, antiviral for CMV, etc.). No approved gene therapy, targeted therapy, or IMD92-specific pharmacotherapy exists, and there are no completed clinical trials (given rarity). NCIT term suggestions: immunoglobulin therapy (NCIT:C583), hematopoietic stem cell transplantation (NCIT:C15431), antibiotic prophylaxis. Pharmacogenomics is not applicable.

13. Prevention

Primary prevention of the genetic defect is not possible; preconception/prenatal genetic counseling in consanguineous families with a known REL variant, plus carrier/cascade testing and preimplantation or prenatal genetic diagnosis, can prevent recurrence. Secondary/tertiary prevention in affected patients: infection prophylaxis, immunoglobulin replacement, aggressive early treatment of infections, and timely HSCT to prevent cumulative organ damage. Immunization caveat: live vaccines are contraindicated in combined immunodeficiency, and responses to inactivated vaccines are poor (documented non-protective titers). Genetic counseling per NSGC/ACMG principles is central.

14. Other Species / Natural Disease

Taxonomy / orthologs: REL is conserved across mammals; the mouse ortholog is Rel (NCBI Gene 19696). No naturally occurring IMD92-equivalent disease has been catalogued in companion animals or wildlife (no OMIA entry noted). Comparative biology: the Rel-knockout mouse (below) demonstrates strong evolutionary conservation of c-Rel's role in lymphocyte activation and humoral immunity. No zoonotic dimension.

15. Model Organisms

The principal model is the Rel-knockout mouse (mammalian germline knockout). It faithfully recapitulates the human disease: normal hematopoietic lineage development but impaired humoral immunity and mature B/T cells unresponsive to most mitogens; PMA+ionomycin bypasses the T-cell proliferation block; exogenous IL-2 restores T- but not B-cell proliferation (Köntgen 1995, PMID: 7649478). Rel-/- T cells show normal activation markers (CD25/CD69/CD62L) but impaired cytokine production and fail to proliferate after anti-CD3/anti-CD28, rescued by IL-2 (Gerondakis 1996, PMID: 8622948). Recapitulation: high for the core immune phenotype (B/T proliferation defect, humoral immunodeficiency, IL-2 dependence). Limitations: mouse models do not capture the human-specific infection spectrum, the neuro-developmental features seen in patient 3, or all human myeloid IL-12/IL-23 nuances. Resources: MGI (Rel); a CRISPR knock-in strategy for conditional human c-Rel expression in mouse T cells has been reported but encountered locus-specific silencing (promoter CpG methylation) challenges (PMID: 41410797).


Evidence Base

PMID Study Role in this report
31103457 Beaussant-Cohen 2019 — Combined immunodeficiency in a patient with c-Rel deficiency First patient; defines disease, splice variant c.535+1G>A, detailed immunophenotype, IVIG+prophylaxis, HSCT evaluation
34623332 Lévy 2021 (JCI) — Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents Second patient; defines the dual myeloid (IL-12/IL-23, CD86) + lymphoid (Treg, memory T/B, NK, IL-2) mechanism
42117340 El-Hamri 2026 — A Novel Biallelic REL Frameshift Variant p.(Tyr9Ilefs*2) Causing IMD92 Third patient; frameshift variant, profound c-Rel deficiency by Western blot, expanded phenotype (craniosynostosis, epilepsy, language delay); confirms AR inheritance and disease name
7649478 Köntgen 1995 (Genes Dev) — Rel-null mice Mouse model recapitulates impaired humoral immunity, mitogen unresponsiveness, IL-2-dependent T-cell rescue
8622948 Gerondakis 1996 (PNAS) — Rel-deficient T cells Confirms lymphocyte activation/humoral defects; IL-3/GM-CSF and cytokine production deficits
35672519 Review — NF-κB in control of regulatory T cell development, identity, and function Supports c-Rel/NF-κB role in Treg biology, linked to human NF-κB-mutation patients
42261849 Review — Inborn Errors of Immunity in the NF-κB Pathway Context: c-Rel within canonical NF-κB; differential diagnosis (RELA, RelB)
41410797 c-Rel conditional knock-in mouse design c-Rel drives IL-2/IFN-γ, represses FOXP3; model-engineering resource and caveats
34473196 NFKB1 variants → AD CVID Differential diagnosis (contrasting NF-κB inborn error, haploinsufficiency)
34695199 WGS of adult T-cell leukemia/lymphoma Contrast: REL 3′-truncations are oncogenic gain-of-function (opposite of IMD92 LOF)

Evidence source types: human clinical (3 case reports), model organism (mouse knockouts), and in vitro functional immunology (patient cell assays). All primary mechanistic and clinical claims are anchored to the citation snippets validated during the investigation.


Limitations and Knowledge Gaps

  1. Extreme rarity (n=3). All clinical conclusions rest on three case reports; prevalence, incidence, penetrance ranges, expressivity, survival, and prognosis cannot be quantified statistically.
  2. Uncertain phenotype boundaries. Craniosynostosis, epilepsy, and language delay were reported in only one patient (patient 3); it is unclear whether these are core IMD92 features, effects of a second recessive locus, or coincidental consanguinity-related findings.
  3. No natural history or registry data. Disease course, long-term HSCT outcomes, and quality-of-life metrics are undefined.
  4. No omics depth. No transcriptomic, proteomic, metabolomic, or single-cell datasets specific to IMD92 patients are published; mechanistic detail derives from targeted assays and mouse models.
  5. No therapeutics evidence base. Treatment recommendations are extrapolated from general CID management and the index case; no trials, response rates, or adverse-event data exist.
  6. Population genetics unknown. Carrier frequencies, founder effects, and geographic variant distribution are uncharacterized.

Proposed Follow-up Experiments / Actions

  1. Establish an international IMD92 patient registry (via IUIS/inborn-errors-of-immunity networks) to aggregate cases, standardize phenotyping, and capture natural history and HSCT outcomes.
  2. Deep immunophenotyping + single-cell RNA-seq of patient PBMCs (and, where available, tissue) to resolve cell-type-specific c-Rel-dependent transcriptional programs and validate the IL-12/IL-23 and IL-2 axis defects at single-cell resolution.
  3. Segregation and additional variant analysis in patient 3 to determine whether craniosynostosis/epilepsy/language delay are REL-attributable or due to a second locus (trio WGS with functional follow-up).
  4. Functional classification pipeline for novel REL variants (κB-reporter and c-Rel Western blot assays), mirroring the NFKB1 approach (PMID: 34473196), to support ACMG variant interpretation and future diagnoses.
  5. Preclinical HSCT / gene-correction studies in the Rel-knockout mouse and patient-derived iPSCs to benchmark curative approaches and inform whether hematopoietic gene therapy is a viable future option.
  6. Curate ontology/database entries (OMIM cross-links, MONDO:0030498, HPO annotations, potential Orphanet/ICD-11 coding) to improve discoverability and standardized annotation of this ultra-rare disorder.

Report compiled from 6 confirmed findings and 16 reviewed papers across a 5-iteration autonomous investigation. Evidence base: human clinical case reports (n=3), mouse knockout models, and in vitro patient-cell functional studies.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 13
On topic 8
Off topic 0

All extracted references resolved successfully.